Lam Research (LRCX) 10-Q8 May 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Mar. 30, 2014	2-May-14
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'LRCX	'
Entity Registrant Name	'LAM RESEARCH CORP	'
Entity Central Index Key	'0000707549	'
Current Fiscal Year End Date	'--06-29	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	162,130,379

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
ASSETS	'	'
Cash and cash equivalents	$1,292,301	$1,162,473	[1]
Short-term investments	1,462,171	1,334,745	[1]
Accounts receivable, less allowance for doubtful accounts of $5,377 as of March 30, 2014 and $5,448 as of June 30, 2013	818,390	602,624	[1]
Inventories	717,356	559,317	[1]
Prepaid expenses and other current assets	157,131	134,670	[1]
Total current assets	4,447,349	3,793,829	[1]
Property and equipment, net	552,591	603,910	[1]
Restricted cash and investments	143,914	166,536	[1]
Goodwill	1,457,320	1,452,196	[1]
Intangible assets, net	951,593	1,074,345	[1]
Other assets	154,600	159,499	[1]
Total assets	7,707,367	7,250,315	[1]
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Trade accounts payable	252,517	200,254	[1]
Accrued expenses and other current liabilities	515,504	464,528	[1]
Deferred profit	257,283	225,038	[1]
Current portion of long-term debt, convertible notes, and capital leases	517,401	514,655	[1]
Total current liabilities	1,542,705	1,404,475	[1]
Long-term debt, convertible notes, and capital leases	810,688	789,256	[1]
Income taxes payable	251,080	246,479	[1]
Other long-term liabilities	111,346	134,313	[1]
Total liabilities	2,715,819	2,574,523	[1]
Commitments and contingencies	'	'	[1]
Senior convertible notes	184,256	186,920	[1]
Stockholders' equity:	'	'
Preferred stock, at par value of $0.001 per share; authorized - 5,000 shares; none outstanding	'	'	[1]
Common stock, at par value of $0.001 per share; authorized - 400,000 shares; issued and outstanding - 161,988 shares as of March 30, 2014 and 162,873 shares as of June 30, 2013	162	163	[1]
Additional paid-in capital	5,187,053	5,084,544	[1]
Treasury stock, at cost; 92,467 shares as of March 30, 2014 and 89,205 shares as of June 30, 2013	-3,724,434	-3,539,830	[1]
Accumulated other comprehensive loss	-27,071	-28,693	[1]
Retained earnings	3,371,582	2,972,688	[1]
Total stockholders' equity	4,807,292	4,488,872	[1]
Total liabilities and stockholders' equity	$7,707,367	$7,250,315	[1]

[1]	Derived from audited financial statements

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, except Per Share data, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Accounts receivable, allowance for doubtful accounts	$5,377	$5,448	[1]
Preferred stock, par value	$0.00	$0.00	[1]
Preferred stock, shares authorized	5,000	5,000	[1]
Preferred stock, shares outstanding	'	'	[1]
Common stock, par value	$0.00	$0.00	[1]
Common stock, shares authorized	400,000	400,000	[1]
Common stock, shares issued	161,988	162,873	[1]
Common stock, shares outstanding	161,988	162,873	[1]
Treasury stock, shares	92,467	89,205	[1]

[1]	Derived from audited financial statements

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Revenue	$1,227,392	$844,928	$3,358,512	$2,612,702
Cost of goods sold	696,594	505,096	1,908,067	1,623,570
Gross margin	530,798	339,832	1,450,445	989,132
Research and development	185,978	174,206	531,022	503,468
Selling, general and administrative	152,883	154,807	457,604	454,091
Total operating expenses	338,861	329,013	988,626	957,559
Operating income	191,937	10,819	461,819	31,573
Other expense, net	-9,855	-15,834	-27,954	-39,162
Income (loss) before income taxes	182,082	-5,015	433,865	-7,589
Income tax expense (benefit)	17,686	-24,011	34,971	-35,761
Net income	$164,396	$18,996	$398,894	$28,172
Net income per share:	'	'	'	'
Basic	$1.01	$0.12	$2.46	$0.16
Diluted	$0.96	$0.11	$2.33	$0.16
Number of shares used in per share calculations:	'	'	'	'
Basic	162,238	163,034	161,904	171,016
Diluted	171,636	168,504	171,051	174,306

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Net income	$164,396	$18,996	$398,894	$28,172
Other comprehensive income (loss), net of tax:	'	'	'	'
Foreign currency translation adjustment	-8,160	-5,398	1,680	-554
Cash flow hedges:	'	'	'	'
Net unrealized gains (losses) during the period	-205	8,400	8,632	10,028
Net gains reclassified into earnings	-3,248	-5,389	-10,066	-3,100
Net change	-3,453	3,011	-1,434	6,928
Available-for-sale investments:	'	'	'	'
Net unrealized gains (losses) during the period	-111	67	962	-105
Net losses (gains) reclassified into earnings	25	2,899	-120	3,321
Net change	-86	2,966	842	3,216
Defined benefit plan, net change in unrealized component	149	160	534	483
Net current-period other comprehensive income	-11,550	739	1,622	10,073
Comprehensive income	$152,846	$19,735	$400,516	$38,245

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014		Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'		'
Net income	$398,894		$28,172
Adjustments to reconcile net income to net cash provided by operating activities:	'		'
Depreciation and amortization	221,139		228,065
Deferred income taxes	11,641		-47,271
Impairment of long-lived asset	11,632		'
Impairment of investments	'		3,711
Equity-based compensation expense	70,615		74,089
Amortization of convertible note discount	24,652		23,530
Other, net	4,428		31,915
Changes in operating assets and liabilities	-271,843		202,734
Net cash provided by operating activities	471,158		544,945
CASH FLOWS FROM INVESTING ACTIVITIES:	'		'
Capital expenditures	-103,739		-117,655
Cash paid for business acquisition	-18,388		-9,116
Purchases of available-for-sale securities	-823,932		-832,913
Sales and maturities of available-for-sale securities	695,001		780,950
Repayments of notes receivable	10,000		'
Proceeds from sale of assets	21,635		660
Transfer of restricted cash and investments	28,722		147
Net cash used for investing activities	-190,701		-177,927
CASH FLOWS FROM FINANCING ACTIVITIES:	'		'
Principal payments on long-term debt and capital lease obligations	-919		-1,536
Excess tax benefit on equity-based compensation plans	-296		-903
Treasury stock purchases	-204,610		-953,386
Reissuances of treasury stock related to employee stock purchase plan	28,329		18,419
Proceeds from issuance of common stock	26,134		22,666
Net cash used for financing activities	-151,362		-914,740
Effect of exchange rate changes on cash	733		2,079
Net increase (decrease) in cash and cash equivalents	129,828		-545,643
Cash and cash equivalents at beginning of period	1,162,473	[1]	1,564,752
Cash and cash equivalents at end of period	$1,292,301		$1,019,109

[1]	Derived from audited financial statements

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Mar. 30, 2014
BASIS OF PRESENTATION	'
	NOTE 1 — BASIS OF PRESENTATION
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements of Lam Research Corporation (“Lam Research” or the “Company”) for the fiscal year ended June 30, 2013, which are included in the Annual Report on Form 10-K as of and for the year ended June 30, 2013 (the “2013 Form 10-K”). The Company’s Forms 10-K, Forms 10-Q and Forms 8-K are available online at the Securities and Exchange Commission website on the Internet. The address of that site is www.sec.gov . The Company also posts its Forms 10-K, Forms 10-Q and Forms 8-K on its corporate website at http://investor.lamresearch.com .
	The consolidated financial statements include the accounts of Lam Research and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting period is a 52/53-week fiscal year. The Company’s current fiscal year (the “2014 fiscal year”) will end June 29, 2014 and includes 52 weeks. The quarter ended March 30, 2014 (the “March 2014 quarter”) included 13 weeks. The quarter ended March 31, 2013 (the “March 2013 quarter”) included 14 weeks.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Mar. 30, 2014
RECENT ACCOUNTING PRONOUNCEMENTS	'
	NOTE 2 — RECENT ACCOUNTING PRONOUNCEMENTS
	In July 2013, the FASB released Accounting Standards Update 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” The new standard requires that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset for a net operating loss carryforward or other tax credit carryforward when settlement in this manner is available under the tax law. We are required to adopt this standard starting fiscal year 2015 and are currently in the process of determining the impact, if any, on our financial position.

EQUITYBASED_COMPENSATION_PLANS

EQUITY-BASED COMPENSATION PLANS	9 Months Ended
EQUITY-BASED COMPENSATION PLANS	Mar. 30, 2014
EQUITY-BASED COMPENSATION PLANS	'
	NOTE 3 — EQUITY-BASED COMPENSATION PLANS
	The Company has stock plans that provide for grants of equity-based awards to eligible participants, including stock options and restricted stock units (“RSUs”), of Lam Research common stock (“Common Stock”). An option is a right to purchase Common Stock at a set price. An RSU award is an agreement to issue shares of Common Stock at the time of vesting. The Company’s options and RSU awards typically vest over a period of three years or less, although awards assumed in connection with the acquisition of Novellus Systems, Inc. (“Novellus”), have vesting terms up to four years. The Company also has an employee stock purchase plan that allows employees to purchase its Common Stock at a discount through payroll deductions.
	The Company recognized the following equity-based compensation expense and related income tax benefit in the Condensed Consolidated Statements of Operations:


		Three Months Ended						Nine Months Ended
		March 30,			March 31,			March 30,		March 31,
		2014			2013			2014		2013
		(in millions)
	Equity-based compensation expense	$	24.3		$	25.6		$	70.6	$	74.1
	Income tax benefit related to equity-based compensation expense	$	4.1		$	4.3		$	11.7	$	13.3
	The estimated fair value of the Company’s stock-based awards, less expected forfeitures, is amortized over the awards’ vesting term on a straight-line basis.
	Stock Options and RSUs
	The Lam Research Corporation 2007 Stock Incentive Plan and 2011 Stock Incentive Plan (collectively the “Stock Plans”) provide for the grant of non-qualified equity-based awards to eligible employees, consultants and advisors, and non-employee directors of the Company and its subsidiaries. As of March 30, 2014, there was a total of 6,395,328 shares reserved to cover options and RSUs issued and outstanding under the Plans. As of March 30, 2014, there were an additional 11,008,283 shares reserved and available for future equity-based awards under the Plans.

	A summary of stock option activity under the Plans as of March 30, 2014 and changes during the nine months then ended is presented below:


	Options	Shares			Weighted-			Weighted-Average		Aggregate Intrinsic
		(in thousands)			Average			Remaining		Value as of
					Exercise Price			Contractual Term		March 30, 2014
								(years)		(in thousands)
	Outstanding at June 30, 2013		2,571		$	26.87			4.48
	Granted		166		$	51.76
	Exercised		(1,065	)	$	24.5
	Forfeited or expired		(1	)	$	29.71

	Outstanding at March 30, 2014		1,671		$	30.86			4.78	$	39,501

	Exercisable at March 30, 2014		1,066		$	24.62			3.86	$	31,840

	The fair value of the Company’s stock options was estimated using a Black-Scholes option valuation model. The total intrinsic value of options exercised during the three months ended March 30, 2014 and March 31, 2013 was $7.1 million and $8.0 million, respectively. The total intrinsic value of options exercised during the nine months ended March 30, 2014 and March 31, 2013 was $29.3 million and $12.7 million, respectively. As of March 30, 2014, there was $5.9 million of total unrecognized compensation cost related to unvested stock options granted and outstanding; that cost is expected to be recognized over a weighted-average remaining vesting period of 1.7 years.
	A summary of the Company’s RSUs as of March 30, 2014 and changes during the nine months then ended is presented below:


		Shares			Average Grant-
	Unvested Restricted Stock Units	(in thousands)			Date Fair Value
	Unvested at June 30, 2013		4,842		$	39.32
	Granted		1,376		$	49.47
	Vested		(1,313	)	$	39.84
	Forfeited		(181	)	$	39.48

	Unvested at March 30, 2014		4,724		$	42.12

	The fair value of the Company’s RSUs was calculated based upon the fair market value of Common Stock at the date of grant. As of March 30, 2014, there was $130.3 million of total unrecognized compensation expense related to unvested RSUs granted; that expense is expected to be recognized over a weighted-average remaining period of 1.9 years.
	During the three months ended March 30, 2014, the Company issued restricted stock units with both a market condition and a service condition (market-based performance RSUs “market-based PRSUs”). Based upon the terms of such awards, the number of shares of Common Stock to be issued at vesting will range from 0% to 150% of the target amount, based on the total stockholder return (“TSR”) of Common Stock measured against the benchmark TSR of the Philadelphia Semiconductor Sector Index over a two and three year period, and continued employment. TSR is a measure of stock price appreciation in this performance period. As of March 30, 2014, 0.6 million market-based PRSUs were outstanding. These market-based performance restricted stock units generally vest two or three years from the grant date. Stock compensation expense for the market-based PRSUs was $1.2 million for the three and nine months ended March 30, 2014. No market-based PRSUs were awarded in earlier periods. The total unrecognized compensation expense and weighted-average remaining life for these awards is included in the above table.
	ESPP
	The 1999 Employee Stock Purchase Plan, as amended and restated (the “1999 ESPP”), allows employees to designate a portion of their base compensation to be withheld through payroll deductions and used to purchase Common Stock at a purchase price per share equal to the lower of 85% of the fair market value of Common Stock on the first or last day of the applicable purchase period. Each offering period generally lasts up to 12 months and includes up to three interim purchase dates. As of March 30, 2014, there was a total of 8,741,208 shares available for issuance under the 1999 ESPP.

	Purchase rights under the 1999 ESPP were valued using the Black-Scholes option valuation model assuming no expected dividends and the following weighted-average assumptions for the three and nine months ended March 30, 2014:


		Three Months Ended			Nine Months Ended
		March 30,			March 30,
		2014			2014
	Expected term (years)		0.51			0.68
	Expected stock price volatility		28.89	%		30.24	%
	Risk-free interest rate		0.09	%		0.07	%
	As of March 30, 2014, there was $5.7 million of unrecognized compensation expense related to the 1999 ESPP, which is expected to be recognized over a remaining period of approximately 5 months.

FINANCIAL_INSTRUMENTS

FINANCIAL INSTRUMENTS	9 Months Ended
FINANCIAL INSTRUMENTS	Mar. 30, 2014
FINANCIAL INSTRUMENTS	'
	NOTE 4 — FINANCIAL INSTRUMENTS
	The Company maintains an investment portfolio of various holdings, types, and maturities. The Company’s mutual funds, which are related to the Company’s obligations under the deferred compensation plan, are classified as trading securities. Investments classified as trading securities are recorded at fair value based upon quoted market prices. Differences between the cost and fair value of trading securities are recognized as other income (expense) in the Condensed Consolidated Statements of Operations. All of the Company’s other short-term investments are classified as available-for-sale and consequently are recorded in the Consolidated Balance Sheets at fair value with unrealized gains or losses reported as a separate component of accumulated other comprehensive income (loss), net of tax.
	Fair Value
	The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability.
	A fair value hierarchy has been established that prioritizes the inputs to valuation techniques used to measure fair value. The level of an asset or liability in the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
	Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities with sufficient volume and frequency of transactions.
	Level 2: Valuations based on observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or model-derived valuations techniques for which all significant inputs are observable in the market or can be corroborated by observable market data, for substantially the full term of the assets or liabilities.
	Level 3: Valuations based on unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities and based on non-binding, broker-provided price quotes and may not have been corroborated by observable market data.

	The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis at March 30, 2014:


							Fair Value Measurement at March 30, 2014
							Quoted Prices in								Significant
							Active Markets for				Significant Other				Unobservable
							Identical Assets				Observable Inputs				Inputs
			Total				(Level 1)				(Level 2)				(Level 3)
			(In thousands)
	Assets
	Short-Term Investments
	Money Market Funds		$	1,042,596			$	1,042,596			$	—			$	—
	Municipal Notes and Bonds			248,949				—				248,949				—
	US Treasury and Agencies			182,967				182,967				—				—
	Government-Sponsored Enterprises			41,089				—				41,089				—
	Foreign Government Bonds			34,988				—				34,988				—
	Corporate Notes and Bonds			961,378				132,549				828,829				—
	Mortgage Backed Securities - Residential			26,580				—				26,580				—
	Mortgage Backed Securities - Commercial			104,857				—				104,857				—

	Total Short-Term Investments		$	2,643,404			$	1,358,112			$	1,285,292			$	—
	Mutual Funds			28,559				28,559				—				—
	Derivative Assets			2,487				—				2,487				—

	Total Assets		$	2,674,450			$	1,386,671			$	1,287,779			$	—

	Liabilities
	Derivative Liabilities		$	1,340			$	—			$	1,190			$	150

	The amounts in the table above are reported in the Consolidated Balance Sheet as of March 30, 2014 as follows:


	Reported Within:		Total				Level 1				Level 2				Level 3
			(In thousands)
	Cash Equivalents		$	1,042,596			$	1,042,596			$	—			$	—
	Short-Term Investments			1,462,171				176,879				1,285,292				—
	Restricted Cash and Investments			138,637				138,637				—				—
	Prepaid Expenses and Other Current Assets			2,487				—				2,487				—
	Other Assets			28,559				28,559				—				—

	Total Assets		$	2,674,450			$	1,386,671			$	1,287,779			$	—

	Accrued Expenses and Other Current Liabilities		$	1,190			$	—			$	1,190			$	—
	Other Non-current Liabilities			150				—				—				150

	Total Liabilities		$	1,340			$	—			$	1,190			$	150

	The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2013:


							Fair Value Measurement at June 30, 2013
			Total				Quoted Prices in				Significant Other				Significant
							Active Markets for				Observable Inputs				Unobservable
							Identical Assets				(Level 2)				Inputs
(Level 1)											(Level 3)
			(In thousands)
Assets
Short-Term Investments
Money Market Funds		$	725,311			$	725,311			$	—			$	—
Municipal Notes and Bonds			268,746				—				268,746				—
US Treasury and Agencies			155,293				155,293				—				—
Government-Sponsored Enterprises			54,805				—				54,805				—
Foreign Government Bond			24,972				—				24,972				—
Corporate Notes and Bonds			860,492				164,885				695,607				—
Mortgage Backed Securities - Residential			27,365				—				27,365				—
Mortgage Backed Securities - Commercial			107,958				—				107,958				—

Total Short-Term Investments		$	2,224,942			$	1,045,489			$	1,179,453			$	—
Equities			7,096				7,096				—				—
Mutual Funds			18,216				18,216				—				—
Derivative Assets			4,929				—				4,929				—

Total Assets		$	2,255,183			$	1,070,801			$	1,184,382			$	—

Liabilities
Derivative Liabilities		$	1,815			$	—			$	1,620			$	195


The amounts in the table above are reported in the Consolidated Balance Sheet as of June 30, 2013 as follows:


Reported Within:		Total				Level 1				Level 2				Level 3
		(In thousands)
Cash Equivalents		$	725,311			$	725,311			$	—			$	—
Short-Term Investments			1,334,746				155,293				1,179,453				—
Restricted Cash and Investments			164,885				164,885				—				—
Prepaid Expenses and Other Current Assets			4,929				—				4,929				—
Other Assets			25,312				25,312				—				—

Total Assets		$	2,255,183			$	1,070,801			$	1,184,382			$	—

Accrued Expenses and Other Current Liabilities		$	1,620			$	—			$	1,620			$	—
Other Non-current Liabilities			195				—				—				195

Total Liabilities		$	1,815			$	—			$	1,620			$	195

The Company’s primary financial instruments include its cash, cash equivalents, short-term investments, restricted cash and investments, long-term investments, accounts receivable, accounts payable, long-term debt and capital leases, and foreign currency related derivatives. The estimated fair value of cash, accounts receivable and accounts payable approximates their carrying value due to the short period of time to their maturities. The estimated fair values of capital lease obligations approximate their carrying value as the substantial majority of these obligations have interest rates that adjust to market rates on a periodic basis. Refer to Note 13 for additional information regarding the fair value of the Company’s convertible notes.

Investments
The following tables summarize the Company’s investments:


		March 30, 2014																June 30, 2013
		Cost				Unrealized				Unrealized				Fair Value				Cost			Unrealized			Unrealized			Fair Value
		Cost				Gain				(Loss)				Fair Value				Cost			Gain			Loss			Fair Value
		(In thousands)																(In thousands)
Cash		$	254,982			$	—			$	—			$	254,982			$	438,813		$	—		$	—		$	438,813
Fixed Income Money Market Funds			1,042,596				—				—				1,042,596				725,311			—			—			725,311
Municipal Notes and Bonds			248,050				927				(28	)			248,949				268,390			805			(449	)		268,746
US Treasury and Agencies			183,072				61				(166	)			182,967				155,648			18			(373	)		155,293
Government-Sponsored Enterprises			41,068				51				(30	)			41,089				54,835			65			(95	)		54,805
Foreign Government Bonds			34,979				95				(86	)			34,988				24,950			47			(25	)		24,972
Corporate Notes and Bonds			960,356				1,771				(749	)			961,378				861,109			1,328			(1,945	)		860,492
Mortgage Backed Securities - Residential			26,802				30				(252	)			26,580				27,618			29			(282	)		27,365
Mortgage Backed Securities - Commercial			105,264				141				(548	)			104,857				108,204			426			(672	)		107,958

Total Cash and Short -Term Investments		$	2,897,169			$	3,076			$	(1,859	)		$	2,898,386			$	2,664,878		$	2,718		$	(3,841	)	$	2,663,755

Publicly Traded Equity Security		$	—			$	—			$	—			$	—			$	5,610		$	1,486		$	—		$	7,096
Private Equity Security			—				—				—				—				5,000			—			—			5,000
Mutual Funds			25,656				2,903				—				28,559				16,611			1,619			(14	)		18,216

Total Financial Instruments		$	2,922,825			$	5,979			$	(1,859	)		$	2,926,945			$	2,692,099		$	5,823		$	(3,855	)	$	2,694,067

Reported Within
Cash and Cash Equivalents		$	1,292,301			$	—			$	—			$	1,292,301			$	1,162,473		$	—		$	—		$	1,162,473
Short-Term Investments			1,460,954				3,076				(1,859	)			1,462,171				1,335,868			2,718			(3,841	)		1,334,745
Restricted Cash and Investments			143,914				—				—				143,914				166,536			—			—			166,536
Other assets			25,656				2,903				—				28,559				27,222			3,105			(14	)		30,313

Total		$	2,922,825			$	5,979			$	(1,859	)		$	2,926,945			$	2,692,099		$	5,823		$	(3,855	)	$	2,694,067

The Company accounts for its investment portfolio at fair value. Realized gains (losses) for investment sales are specifically identified. Management assesses the fair value of investments in debt securities that are not actively traded through consideration of interest rates and their impact on the present value of the cash flows to be received from the investments. The Company also considers whether changes in the credit ratings of the issuer could impact the assessment of fair value. The Company did not recognize any losses on investments due to other-than-temporary impairments during the three and nine months ended March 30, 2014. The Company recognized a $3.7 million other-than-temporary impairment of a public equity investment during the three and nine months ended March 31, 2013. Additionally, gross realized gains and gross realized (losses) from sales of investments were approximately $0.4 million and $(0.7) million, respectively, in the three months ended March 30, 2014 and $0.2 million and $(0.4) million, respectively, in the three months ended March 31, 2013. Gross realized gains and gross realized (losses) from sales of investments were approximately $0.8 million and $(1.7) million, respectively, in the nine months ended March 30, 2014 and $1.4 million and $(1.1) million, respectively, in the nine months ended March 30, 2013.
The following is an analysis of the Company’s fixed income securities in unrealized loss positions:


		March 30, 2014
		Unrealized Losses								Unrealized Losses
		Less Than 12 Months								12 Months or Greater								Total
		Fair Value				Gross				Fair Value				Gross				Fair Value			Gross
						Unrealized								Unrealized							Unrealized
						Loss								Loss							Loss
		(In thousands)
Short-Term Investments
Municipal Notes and Bonds		$	17,114			$	(28	)		$	—			$	—			$	17,114		$	(28	)
US Treasury and Agencies			96,394				(166	)			—				—				96,394			(166	)
Government-Sponsored Enterprises			14,071				(30	)			—				—				14,071			(30	)
Foreign Government Bonds			18,487				(86	)			—				—				18,487			(86	)
Corporate Notes and Bonds			261,299				(729	)			6,465				(20	)			267,764			(749	)
Mortgage Backed Securities - Residential			20,974				(243	)			127				(9	)			21,101			(252	)
Mortgage Backed Securities - Commercial			75,081				(404	)			4,249				(144	)			79,330			(548	)

Total Short-Term Investments		$	503,420			$	(1,686	)		$	10,841			$	(173	)		$	514,261		$	(1,859	)


The amortized cost and fair value of cash equivalents, short-term investments, and restricted cash and investments with contractual maturities are as follows as of March 30, 2014:


		Cost				Estimated Fair
		Cost				Value
		(in thousands)
Due in one year or less		$	1,316,589			$	1,317,140
Due after one year through five years			1,035,559				1,036,852
Due in more than five years			290,039				289,412

		$	2,642,187			$	2,643,404

Management has the ability, if necessary, to liquidate its cash equivalents and short-term investments in order to meet the Company’s liquidity needs in the next 12 months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase nonetheless are classified as short-term on the accompanying Consolidated Balance Sheets.
Derivative Instruments and Hedging
The Company carries derivative financial instruments (“derivatives”) on its Consolidated Balance Sheets at their fair values. The Company enters into foreign currency forward contracts with financial institutions with the primary objective of reducing volatility of earnings and cash flows related to foreign currency exchange rate fluctuations. The counterparties to these forward contracts are large global financial institutions that the Company believes are creditworthy, and therefore, we do not consider the risk of counterparty nonperformance to be material.
Cash Flow Hedges
The Company’s financial position is routinely subjected to market risk associated with foreign currency exchange rate fluctuations on non-U.S. dollar transactions or cash flows, primarily from Japanese yen-denominated revenues and euro-denominated expenses. The Company’s policy is to mitigate the foreign exchange risk arising from the fluctuations in the value of these non-U.S. dollar denominated transactions or cash flows through a foreign currency cash flow hedging program, using forward contracts that generally expire within 12 months and no later than 24 months. These foreign currency forward contracts are designated as cash flow hedges and are carried on the Company’s balance sheet at fair value with the effective portion of the contracts’ gains or losses included in accumulated other comprehensive income (loss) and subsequently recognized in revenue/expense in the same period the hedged items are recognized.
At inception and at each quarter end, hedges are tested prospectively and retrospectively for effectiveness using regression analysis. Changes in the fair value of the forward contracts due to changes in time value are excluded from the assessment of effectiveness and are recognized in revenue or expense in the current period. The change in time value related to these contracts was not material for all reported periods. To qualify for hedge accounting, the hedge relationship must meet criteria relating both to the derivative instrument and the hedged item. These criteria include identification of the hedging instrument, the hedged item, the nature of the risk being hedged and how the hedging instrument’s effectiveness in offsetting the exposure to changes in the hedged item’s fair value or cash flows will be measured. There were no gains or losses during the three and nine months ended March 30, 2014 or March 31, 2013 associated with ineffectiveness or forecasted transactions that failed to occur.
To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge and the hedges must be tested to demonstrate an expectation of providing highly effective offsetting changes to future cash flows on hedged transactions. When derivative instruments are designated and qualify as effective cash flow hedges, the Company recognizes effective changes in the fair value of the hedging instrument within accumulated other comprehensive income (loss) until the hedged exposure is realized. Consequently, with the exception of excluded time value and hedge ineffectiveness recognized, the Company’s results of operations are not subject to fluctuation as a result of changes in the fair value of the derivative instruments. If hedges are not highly effective or if the Company does not believe that the underlying hedged forecasted transactions will occur, the Company may not be able to account for its derivative instruments as cash flow hedges. If this were to occur, future changes in the fair values of the Company’s derivative instruments would be recognized in earnings. Additionally, related amounts previously recorded in other comprehensive income would be reclassified to income immediately. At March 30, 2014, the Company had gains of $1.4 million accumulated in other comprehensive income, which it expects to reclassify from other comprehensive income into earnings over the next 12 months.
Balance Sheet Hedges
The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily third party accounts receivables, accounts payables and intercompany receivables and payables. These forward contracts are not designated for hedge accounting treatment. Therefore, the change in fair value of these derivatives is recorded as a component of other income (expense) and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other income (expense).

As of March 30, 2014, the Company had the following outstanding foreign currency forward contracts that were entered into under its cash flow and balance sheet hedge program:


		Derivatives Designated as								Derivatives Not Designated as
		Hedging Instruments:								Hedging Instruments:
		(in thousands)
Foreign Currency Forward Contracts
		Buy Contracts				Sell Contracts				Buy Contracts				Sell Contracts
Japanese Yen		$	—			$	123,282			$	—			$	65,959
Swiss Franc											7,496				—
Euro			60,487				—				—				8,901
Korean Won			—				—				36,386				—
Taiwan Dollar			—				—				188,583				65,899

		$	60,487			$	123,282			$	232,465			$	140,759

The fair value of derivative instruments in the Company’s Consolidated Balance Sheets as of March 30, 2014 and June 30, 2013 were as follows:


		March 30, 2014												June 30, 2013
		Fair Value of Derivative Instruments												Fair Value of Derivative Instruments
		Asset Derivatives						Liability Derivatives						Asset Derivatives						Liability Derivatives
		Balance Sheet		Fair Value				Balance Sheet		Fair Value				Balance Sheet		Fair Value				Balance Sheet	Fair
		Location		Fair Value				Location		Fair Value				Location		Fair Value				Location	Value
		(in thousands)
Derivatives designated as hedging instruments:
Foreign exchange forward contracts		Prepaid expense and other assets		$	2,297			Accrued liabilities		$	619			Prepaid expense and other assets		$	4,858			Accrued	$	1,577
Foreign exchange forward contracts		Prepaid expense and other assets		$	2,297			Accrued liabilities		$	619			Prepaid expense and other assets		$	4,858			liabilities	$	1,577
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts		Prepaid expense and other assets			190			Accrued liabilities			571			Prepaid expense and other assets			71			Accrued		43
Foreign exchange forward contracts		Prepaid expense and other assets			190			Accrued liabilities			571			Prepaid expense and other assets			71			liabilities		43

Total derivatives				$	2,487					$	1,190					$	4,929				$	1,620

Under the master netting agreements with the respective counterparties to the Company’s foreign exchange contracts, subject to applicable requirements, the Company is allowed to net settle transactions of the same currency with a single net amount payable by one party to the other. However, the Company has elected to present the derivative assets and derivative liabilities on a gross basis in its balance sheet. As of March 30, 2014, the potential effect of netting the above foreign exchange contracts would be an offset to assets and liabilities by $0.7 million, resulting in a net derivative asset of $1.3 million. As of June 30, 2013, the potential effect of netting the above foreign exchange contracts was an offset to both assets and liabilities by $1.6 million, resulting in a net derivative asset of $3.3 million. The Company is not required to pledge, nor is the Company entitled to receive, cash collateral for these derivative transactions.

The effect of derivative instruments designated as cash flow hedges on the Company’s Condensed Consolidated Statements of Operations, including accumulated other comprehensive income (“AOCI”) was as follows:


		Three Months Ended March 30, 2014												Nine Months Ended March 30, 2014
		Effective Portion								Ineffective Portion and				Effective Portion							Ineffective Portion and
										Amount Excluded from											Amount Excluded from
										Effectiveness Testing											Effectiveness Testing
Location of Gain (Loss) Recognized in or		Gain (Loss)				Gain				Gain (Loss)				Gain				Gain			Gain (Loss)
Reclassified into Income		Recognized				Reclassified				Recognized				Recognized				Reclassified			Recognized
		in AOCI				from AOCI				in Income				in AOCI				from AOCI			in Income
						into Income												into Income
		(in thousands)												(in thousands)
Revenue		$	(621	)		$	2,787			$	54			$	7,483			$	8,947		$	232
Cost of goods sold			307				646				(10	)			1,717				1,764			(66	)
Selling, general, and administrative			112				291				(5	)			667				800			(29	)
Other income (expense)			—				—				—				—				—			—

		$	(202	)		$	3,724			$	39			$	9,867			$	11,511		$	137


		Three Months Ended March 31, 2013												Nine Months Ended March 31, 2013
		Effective Portion								Ineffective Portion and				Effective Portion							Ineffective Portion and
										Amount Excluded from											Amount Excluded from
										Effectiveness Testing											Effectiveness Testing
Location of Gain (Loss) Recognized in or		Gain (Loss)				Gain				Gain (Loss)				Gain				Gain (Loss)			Gain (Loss)
Reclassified into Income		Recognized				Reclassified				Recognized				Recognized				Reclassified			Recognized
		in AOCI				from AOCI				in Income				in AOCI				from AOCI			in Income
						into Income												into Income
		(in thousands)												(in thousands)
Revenue		$	9,454			$	3,850			$	78			$	8,159			$	4,574		$	274
Cost of goods sold			(563	)			1,194				(44	)			1,332				(1,069	)		(208	)
Selling, general, and administrative			(491	)			345				(20	)			537				(405	)		(100	)
Other income (expense)			—				—				—				—				—			(8	)

		$	8,400			$	5,389			$	14			$	10,028			$	3,100		$	(42	)

The effect of derivative instruments not designated as cash flow hedges on the Company’s Condensed Consolidated Statements of Operations was as follows:


				Three Months Ended								Nine Months Ended
				March 30, 2014				March 31, 2013				March 30, 2014				March 31, 2013
Derivatives Not Designated		Location of Gain (Loss) Recognized in		Loss				Gain				Gain				Gain
as Hedging Instruments:		Income		Recognized				Recognized				Recognized				Recognized
				in Income				in Income				in Income				in Income
				(in thousands)
Foreign Exchange Contracts		Other income (expense)		$	(6,527	)		$	2,061			$	4,512			$	2,347
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term investments, restricted cash and investments, trade accounts receivable, and derivative financial instruments used in hedging activities. Cash is placed on deposit at large global financial institutions. Such deposits may be in excess of insured limits. Management believes that the financial institutions that hold the Company’s cash are creditworthy and, accordingly, minimal credit risk exists with respect to these balances.
The Company’s overall portfolio of available-for-sale securities must maintain an average minimum rating of “AA-” or “Aa3” as rated by Standard and Poor’s or Moody’s Investor Services, respectively. To ensure diversification and minimize concentration, the Company’s policy limits the amount of credit exposure with any one financial institution or commercial issuer.
The Company is exposed to credit losses in the event of nonperformance by counterparties on the foreign currency forward hedge contracts and on structured share repurchase arrangements. These counterparties are large global financial institutions and, to date, no such counterparty has failed to meet its financial obligations to the Company.
Credit risk evaluations, including trade references, bank references and Dun & Bradstreet ratings, are performed on all new customers and the Company monitors its customers’ financial statements and payment performance. In general, the Company does not require collateral on sales.

INVENTORIES

INVENTORIES	9 Months Ended
INVENTORIES	Mar. 30, 2014
INVENTORIES	'
	NOTE 5 — INVENTORIES
	Inventories are stated at the lower of cost (first-in, first-out method) or market. Shipments to Japanese customers, to whom title does not transfer until customer acceptance, are classified as finished goods inventory and carried at cost until title transfers. Inventories consist of the following:


		March 30,		June 30,
		2014		2013
		(in thousands)
	Raw materials	$	440,772	$	312,484
	Work-in-process		114,890		101,530
	Finished goods		161,694		145,303

		$	717,356	$	559,317

PROPERTY_AND_EQUIPMENT_NET

PROPERTY AND EQUIPMENT, NET	9 Months Ended
PROPERTY AND EQUIPMENT, NET	Mar. 30, 2014
PROPERTY AND EQUIPMENT, NET	'
	NOTE 6 — PROPERTY AND EQUIPMENT, NET
	Property and equipment, net, consists of the following:


		March 30,			June 30,
		2014			2013
		(in thousands)
	Manufacturing, engineering and office equipment	$	590,505		$	521,047
	Computer equipment and software		128,753			120,144
	Land		55,951			65,360
	Buildings		207,537			249,126
	Leasehold improvements		79,152			76,225
	Furniture and fixtures		24,824			21,110

			1,086,722			1,053,012
	Less: accumulated depreciation and amortization		(534,131	)		(449,102	)

		$	552,591		$	603,910

	During the nine months ended March 30, 2014, the Company sold or reclassified to assets held-for-sale property and equipment with a net book value of $69 million as a result of facility consolidation. These assets consisted primarily of buildings and land, resulting in the decreases to those asset categories in the table above.

GOODWILL_AND_INTANGIBLE_ASSETS

GOODWILL AND INTANGIBLE ASSETS	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS	Mar. 30, 2014
GOODWILL AND INTANGIBLE ASSETS	'
	NOTE 7 — GOODWILL AND INTANGIBLE ASSETS
	Goodwill
	There was no significant change in the goodwill balance during the nine months ended March 30, 2014. Of the $1.5 billion goodwill balance as of March 30, 2014, $61 million is tax deductible and the remaining balance is not tax deductible due to purchase accounting and applicable foreign law.
	Goodwill is assessed at least annually for impairment. The Company did not record impairments of goodwill during the three or nine months ended March 30, 2014 or March 31, 2013.

	Intangible Assets
	The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of March 30, 2014:


		Gross		Accumulated			Net		Weighted-Average
		Gross		Amortization			Net		Useful Life
		(in thousands)							(years)
	Customer relationships	$	625,072	$	(156,121	)	$	468,951		9.01
	Existing technology		662,357		(207,981	)		454,376		6.96
	Patents		32,053		(23,887	)		8,166		6.09
	Other intangible assets		35,216		(35,216	)		—		4.1

	Intangible assets subject to amortization		1,354,698		(423,205	)		931,493
	In process research and development		11,000					11,000
	Development rights		9,100					9,100

	Intangible assets not subject to amortization		20,100					20,100

	Total intangible assets	$	1,374,798	$	(423,205	)	$	951,593

	The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of June 30, 2013 (in thousands, except years):


		Gross		Accumulated			Net		Weighted-Average
		Gross		Amortization			Net		Useful Life
		(in thousands)							(years)
	Customer relationships	$	624,686	$	(103,519	)	$	521,167		9.01
	Existing technology		653,628		(139,894	)		513,734		6.97
	Patents		32,053		(22,036	)		10,017		6.09
	Backlog		10,000		(10,000	)		—		1
	Other intangible assets		35,216		(34,889	)		327		4.1

	Intangible assets subject to amortization		1,355,583		(310,338	)		1,045,245
	In process research and development		20,000					20,000
	Development rights		9,100					9,100

	Intangible assets not subject to amortization		29,100					29,100

	Total intangible assets	$	1,384,683	$	(310,338	)	$	1,074,345

	The Company recognized $40.4 million and $45.0 million in intangible asset amortization expense during the three months ended March 30, 2014 and March 31, 2013, respectively. The Company recognized $122.9 million and $134.3 million in intangible asset amortization expense during the nine months ended March 30, 2014 and March 31, 2013, respectively. The Company recognized a $4.0 million impairment of in process research and development during the three and nine months ended March 31, 2014 due to the cancellation of a project.
	The estimated future amortization expense of purchased intangible assets as of March 30, 2014 is as follows:


	Fiscal Year	Amount
		(in thousands)
	2014 (3 months)	$	39,842
	2015		159,718
	2016		157,510
	2017		155,790
	2018		154,625
	Thereafter		264,008

		$	931,493

ACCRUED_EXPENSES_AND_OTHER_CUR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	9 Months Ended
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	Mar. 30, 2014
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	'
	NOTE 8 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
	Accrued expenses and other current liabilities consist of the following:


		March 30,		June 30,
		2014		2013
		(in thousands)
	Accrued compensation	$	283,594	$	254,795
	Warranty reserves		71,489		52,252
	Income and other taxes payable		51,178		39,420
	Other		109,243		118,061

		$	515,504	$	464,528

OTHER_EXPENSE_NET

OTHER EXPENSE, NET	9 Months Ended
OTHER EXPENSE, NET	Mar. 30, 2014
OTHER EXPENSE, NET	'
	NOTE 9 — OTHER EXPENSE, NET
	The significant components of other expense, net, are as follows:


		Three Months Ended						Nine Months Ended
		March 30,			March 31,			March 30,			March 31,
		2014			2013			2014			2013
		(in thousands)
	Interest income	$	3,110		$	3,235		$	8,661		$	11,411
	Interest expense		(15,621	)		(15,175	)		(46,220	)		(45,294	)
	Gains on deferred compensation plan related assets		3,137			3,112			8,534			7,087
	Foreign exchange gains (losses)		(85	)		(1,294	)		(181	)		(4,936	)
	Other, net		(396	)		(5,712	)		1,252			(7,430	)

		$	(9,855	)	$	(15,834	)	$	(27,954	)	$	(39,162	)

INCOME_TAX_EXPENSE

INCOME TAX EXPENSE	9 Months Ended
INCOME TAX EXPENSE	Mar. 30, 2014
INCOME TAX EXPENSE	'
	NOTE 10 — INCOME TAX EXPENSE
	The Company recorded an income tax expense of $17.7 million and $35.0 million for the three and nine months ended March 30, 2014, respectively, which yielded an effective tax rate for the three and nine months ended March 30, 2014 of approximately 9.7% and 8.1%, respectively. The difference between the U.S. federal statutory tax rate of 35% and the Company’s effective tax rate for the three and nine months ended March 30, 2014 is primarily due to the geographic mix of income and the recognition of previously unrecognized tax benefits due to lapse of statutes of limitation, offset by the tax effect of non-deductible stock-based compensation and unrecognized tax benefits due to uncertain tax positions.

NET_INCOME_PER_SHARE

NET INCOME PER SHARE	9 Months Ended
NET INCOME PER SHARE	Mar. 30, 2014
NET INCOME PER SHARE	'
	NOTE 11 — NET INCOME PER SHARE
	Basic net income per share is computed by dividing net income by the weighted-average number of shares of Common Stock outstanding during the period. Diluted net income per share is computed using the treasury stock method, for dilutive stock options, RSUs, and convertible notes. Dilutive shares outstanding include only the effect of the 2041 Notes. The following table reconciles the numerators and denominators of the basic and diluted computations for net income per share.


		Three Months Ended				Nine Months Ended
		March 30,		March 31,		March 30,		March 31,
		2014		2013		2014		2013
		(in thousands, except per share data)
	Numerator:
	Net income	$	164,396	$	18,996	$	398,894	$	28,172

	Denominator:
	Basic average shares outstanding		162,238		163,034		161,904		171,016
	Effect of potential dilutive securities:
	Employee stock plans		2,641		2,729		2,810		2,390
	Convertible notes		6,757		2,741		6,337		900

	Diluted average shares outstanding		171,636		168,504		171,051		174,306

	Net income per share - basic	$	1.01	$	0.12	$	2.46	$	0.16

	Net income per share - diluted	$	0.96	$	0.11	$	2.33	$	0.16


	For purposes of computing diluted net income per share, weighted-average common shares do not include potentially dilutive securities that are anti-dilutive under the treasury stock method. The following potentially dilutive securities were excluded:


		Three Months Ended				Nine Months Ended
		March 30,		March 31,		March 30,		March 31,
		2014		2013		2014		2013
		(in thousands)
	Number of potential dilutive securities excluded		75		298		85		567

	Diluted shares outstanding do not include any effect resulting from warrants, assumed conversion of the notes, or note hedges associated with the Company’s 2016 or 2018 Notes (as described in Note 13) as their impact would have been anti-dilutive.

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE LOSS	9 Months Ended
ACCUMULATED OTHER COMPREHENSIVE LOSS	Mar. 30, 2014
ACCUMULATED OTHER COMPREHENSIVE LOSS	'
	NOTE 12 — ACCUMULATED OTHER COMPREHENSIVE LOSS
	The components of accumulated other comprehensive income (loss), net of tax at the end of the period, as well as the activity during the period, were as follows:


			Accumulated			Accumulated			Accumulated			Accumulated			Total
			foreign			unrealized			unrealized			unrealized
			currency			holding gain			holding gain			components
			translation			(loss) on cash			(loss) on			of defined
			adjustment			flow hedges			available-for-sale			benefit plans
									investments
			(in thousands)
	Balance as of June 30, 2013		$	(17,178	)	$	2,822		$	(15	)	$	(14,322	)	$	(28,693	)
	Other comprehensive income before reclassifications			1,680			8,632			962			534			11,808
	Gains reclassified from accumulated other comprehensive income to net income			—			(10,066	) (1)		(120	) (2)		—			(10,186	)

	Net current-period other comprehensive income		$	1,680		$	(1,434	)	$	842		$	534		$	1,622

	Balance as of March 30, 2014		$	(15,498	)	$	1,388		$	827		$	(13,788	)	$	(27,071	)


	-1	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in revenue: $7,961, cost of goods sold: $1,505 and selling, general and administrative expenses: $600.
	-2	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in other expense, net.

LONGTERM_DEBT_AND_OTHER_BORROW

LONG-TERM DEBT AND OTHER BORROWINGS	9 Months Ended
LONG-TERM DEBT AND OTHER BORROWINGS	Mar. 30, 2014
LONG-TERM DEBT AND OTHER BORROWINGS	'
	NOTE 13 — LONG-TERM DEBT AND OTHER BORROWINGS
	The following table reflects the carrying value of the Company’s convertible senior notes and other long-term debt as of March 30, 2014 and June 30, 2013:


		March 30,			June 30,
		2014			2013
		(in millions)
	0.50% Notes due 2016	$	450		$	450
	Less: Unamortized interest discount		(34.3	)		(45.7	)

	Net carrying amount of 0.50% Notes due 2016		415.7			404.3

	1.25% Notes due 2018		450			450
	Less: Unamortized interest discount		(66.3	)		(76.9	)

	Net carrying amount of 1.25% Notes due 2018		383.7			373.1

	2.625% Notes due 2041		699.9			699.9
	Less: Unamortized interest discount		(184.2	)		(186.9	)

	Net carrying amount of 2.625% Notes due 2041		515.7			513

	Total debt		1,315.10			1,290.40

	Less: current portion of debt		(515.7	)		(513.0	)

	Long-term debt	$	799.4		$	777.4

	Convertible Senior Notes
	In May 2011, the Company issued and sold $450.0 million in aggregate principal amount of 0.50% Convertible Senior Notes due May 2016 (the “2016 Notes”) at par. At the same time, the Company issued and sold $450.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due May 2018 (the “2018 Notes”) at par. The 2016 Notes and the 2018 Notes may be converted, under certain circumstances, based on an initial conversion rate of 15.8687 shares of Common Stock per $1,000 principal amount of notes (which represents an initial conversion price of approximately $63.02 per share of Common Stock).The net proceeds to the Company from the sale of the 2016 Notes and the 2018 Notes were $835.5 million. The Company pays cash interest at an annual rate of 0.5% and 1.25%, respectively, on the 2016 Notes and the 2018 Notes, on a semi-annual basis on May 15 and November 15 of each year.
	In June 2012, with the acquisition of Novellus, the Company assumed $700.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due May 2041 (the “2041 Notes,” and collectively with the 2016 Notes and the 2018 Notes, the “Notes”). The 2041 Notes may be converted, under certain circumstances, based on an initial conversion rate of 28.4781 shares of Common Stock per $1,000 principal amount of notes (which represents an initial conversion price of approximately $35.11 per share of Common Stock). The Company pays cash interest at an annual rate of 2.625%, on a semi-annual basis on May 15 and November 15 of each year. The 2041 Notes also have a contingent interest payment provision that may require the Company to pay additional interest based on certain thresholds, beginning with the semi-annual interest payment commencing on May 15, 2021, and upon the occurrence of certain events, as outlined in the indenture governing the 2041 Notes. The maximum amount of the contingent interest will accrue at a rate of 2.1% per annum, excluding any potential impact from dividends deemed payable to holders of the 2041 Notes. The contingent interest payment provision has been identified as an embedded derivative, to be accounted for separately, and is recorded at fair value at the end of each reporting period in other non-current liabilities, with any gains and losses recorded in interest expense, within the Condensed Consolidated Statements of Operations.
	The Company separately accounts for the liability and equity components of the Notes. The initial debt components of the 2016 Notes, the 2018 Notes, and the 2041 Notes were valued at $373.8 million, $345.1 million, and $509.5 million, respectively, based on the present value of the future cash flows using discount rates of 4.29%, 5.27%, and 4.28%, respectively, the Company’s borrowing rate at the date of the issuance or assumption for similar debt instruments without the conversion feature. The carrying values of the equity components of the 2016 Notes, the 2018 Notes, and the 2041 Notes were $76.2 million, $104.9 million, and $328.1 million, respectively as of March 30, 2014. The effective interest rates on the liability components of the 2016 Notes, the 2018 Notes, and the 2041 Notes for the three and nine months ended March 30, 2014 were 4.29%, 5.27%, and 4.28%, respectively. The following table presents the amount of interest cost recognized relating to both the contractual interest coupon and amortization of the discount on the liability component of the Notes during the three and nine months ended March 30, 2014 and March 31, 2013.


		Three Months Ended						Nine Months Ended
		March 30,			March 31,			March 30,		March 31,
		2014			2013			2014		2013
		(in millions)
	Contractual interest coupon	$	6.6		$	6.6			19.7		19.7
	Amortization of interest discount		8.3			7.9			24.7		23.5
	Amortization of issuance costs		0.6			0.6			1.8		1.8

	Total interest cost recognized	$	15.5		$	15.1		$	46.2	$	45


	The remaining bond discount of the 2016 Notes, the 2018 Notes, and the 2041 Notes of $34.3 million, $66.3 million, and $184.2 million, respectively, as of March 30, 2014 will be amortized over their respective remaining lives of approximately 2.1 years, 4.1 years, and 27.1 years. As of March 30, 2014, the if-converted value of the 2016 Notes and 2018 Notes did not exceed the aggregate principal amount. As of March 30, 2014, the if-converted value of the 2041 Notes exceeded the aggregate principal amount by $386.3 million.
	Convertible Note Hedges and Warrants
	Concurrently with the issuance of the 2016 Notes and the 2018 Notes, the Company purchased convertible note hedges and sold warrants. The separate convertible note hedge and warrant transactions are collectively structured to reduce the potential future economic dilution associated with the conversion of the 2016 Notes and the 2018 Notes and to increase the effective initial conversion price to $71.34 and $76.10 per share, respectively. Each of these components is discussed below.
	Concurrent with the issuance of the 2016 Notes, the Company sold warrants to purchase up to approximately 7.1 million shares of Common Stock at an exercise price of $71.34 per share. The warrants expire on a series of dates between August 15, 2016 and October 21, 2016. At expiration, the Company may, at its option, elect to settle the warrants on a net share basis. As of March 30, 2014, the warrants had not been exercised and remained outstanding. In addition, counterparties agreed to sell to the Company up to approximately 7.1 million shares of Common Stock, which is the number of shares initially issuable upon conversion of the 2016 Notes in full, at a price of $63.02 per share. The convertible note hedge transaction will be settled in net shares and will terminate upon the earlier of the maturity date of the 2016 Notes or the first day none of the 2016 Notes remains outstanding due to conversion or otherwise. Settlement of the convertible note hedge in net shares, based on the number of shares issued upon conversion of the 2016 Notes, on the expiration date would result in the Company receiving net shares equivalent to the number of shares issuable by the Company upon conversion of the 2016 Notes.
	Concurrent with the issuance of the 2018 Notes, the Company sold warrants to purchase up to approximately 7.1 million shares of Common Stock at an exercise price of $76.10 per share. The warrants expire on a series of dates between August 15, 2018 and October 23, 2018. At expiration, the Company may, at its option, elect to settle the warrants on a net share basis. As of March 30, 2014, the warrants had not been exercised and remained outstanding. In addition, counterparties agreed to sell to the Company up to approximately 7.1 million shares of Common Stock, which is the number of shares initially issuable upon conversion of the 2018 Notes in full, at a price of $63.02 per share. The convertible note hedge transaction will be settled in net shares and will terminate upon the earlier of the maturity date of the 2018 Notes or the first day none of the 2018 Notes remains outstanding due to conversion or otherwise. Settlement of the convertible note hedge in net shares, based on the number of shares issued upon conversion of the 2018 Notes, on the expiration date would result in the Company receiving net shares equivalent to the number of shares issuable by the Company upon conversion of the 2018 Notes.
	Conversion Period
	During the fiscal quarters ended June 30, 2013, December 29, 2013 and March 30, 2014 the market value of the Common Stock was greater than or equal to 130% of the 2041 Note conversion price for 20 or more trading days of the 30 consecutive trading days preceding the quarter end. As a result, the 2041 Notes became convertible at the option of the holder anytime during the fiscal quarters ending December 29, 2013 and continue to be convertible through June 29, 2014 (the “June 2014 quarter”). However, there were no conversions of the 2041 Notes during the March 2014 quarter or the June 2014 quarter as of May 5, 2014.
	As a result of the open conversion period, the carrying amount of the 2041 Notes was classified in current liabilities in the Company’s Consolidated Balance Sheets as of March 30, 2014 and June 30, 2013. The excess of the amount of cash payable, if converted, over the carrying amount of the 2041 Notes was classified as temporary equity as of March 30, 2014 and June 30, 2013. Upon closure of a conversion period, all 2041 Notes not converted will be reclassified back to noncurrent liabilities and the temporary equity is reclassified to permanent equity.
	Fair Value of Notes
	As of March 30, 2014, the face values of the 2016 Notes, the 2018 Notes, and the 2041 Notes were $450.0 million, $450.0 million, and $699.9 million, respectively. As of March 30, 2014, the fair values of the 2016 Notes, the 2018 Notes, and the 2041 Notes, which includes the debt and equity components, were approximately $518.6 million, $558.4 million, and $1,196.9 million, respectively, based on quoted market prices (Level 1 inputs within the fair value hierarchy).
	Revolving Credit Facility
	On March 12, 2014 the Company entered into a $300 million revolving unsecured credit facility with a syndicate of lenders that matures on March 12, 2019. The facility includes an option for the Company to, subject to certain requirements, request an increase in the facility of up to an additional $200 million, for a potential total commitment of $500 million. Proceeds from the credit facility can be used for general corporate purposes.
	Interest on amounts borrowed under the credit facility is, at the Company’s option, based on (i) a base rate, defined as the greatest of (a) prime rate, (b) Federal Funds rate plus 0.5%, or (c) one-month LIBOR plus 1.0%, plus a spread of 0.0% to 0.5%, or (ii) LIBOR plus a spread of 0.9% to 1.5%, in each case the applicable spread is determined based on the rating of the Company’s non-credit enhanced, senior unsecured long-term debt. Principal, and any accrued and unpaid interest, is due and payable upon maturity. Additionally, the Company will pay the lenders a quarterly commitment fee that varies based on the Company’s rating described above. The credit facility contains certain restrictive covenants including maintaining a total consolidated indebtedness to consolidated capitalization ratio of no more than 0.5 to 1.0 and maintaining unrestricted or unencumbered cash and investments of no less than $1.0 billion. As of March 30, 2014, we had no borrowings outstanding under the credit facility and were in compliance with all financial covenants.

COMMITMENTS

COMMITMENTS	9 Months Ended
COMMITMENTS	Mar. 30, 2014
COMMITMENTS	'
	NOTE 14 — COMMITMENTS
	Operating Leases and Related Guarantees
	The Company leases certain of its administrative, research and development (“R&D”) and manufacturing facilities, regional sales/service offices and certain equipment under non-cancelable operating leases. Certain of the Company’s facility leases for buildings located at its Fremont, California headquarters and certain other facility leases provide the Company with options to extend the leases for additional periods or to purchase the facilities. Certain of the Company’s facility leases provide for periodic rent increases based on the general rate of inflation.
	On December 31, 2013, the Company extinguished its two operating leases regarding certain improved properties in Livermore, California and its four amended and restated operating leases regarding certain improved properties in Fremont, California and entered into six amended operating leases (the “Operating Leases”) regarding certain improved properties at the Company’s headquarters in Fremont, California and certain other improved properties in Livermore, California.
	The Operating Leases have a term of approximately seven years ending on December 31, 2020. The Company may, at its discretion and with 30 days’ notice, elect to purchase the property that is the subject of the Operating Leases for an amount approximating the sum required to pay the amount of the lessor’s investment in the property and any accrued but unpaid rent.
	As of March 30, 2014, the Company was required, pursuant to the terms of the Operating Leases, to maintain cash collateral in an aggregate of approximately $132.5 million in separate interest-bearing accounts and marketable securities collateral in an aggregate of approximately $6.1 million as security for the Company’s obligations under the Operating Leases. These amounts are recorded as restricted cash and investments in the Company’s Consolidated Balance Sheet as of March 30, 2014.
	During the term of the Operating Leases and when the terms of the Operating Leases expire, the property subject to those Operating Leases may be remarketed. The Company has guaranteed to the lessor that each property will have a certain minimum residual value. The aggregate guarantee made by the Company under the Operating Leases is generally no more than approximately $191.2 million; however, under certain default circumstances, the guarantee with regard to an Operating Lease may be 100% of the lessor’s aggregate investment in the applicable property, which in no case will exceed $220.0 million, in the aggregate.
	Other Guarantees
	The Company has issued certain indemnifications to its lessors for taxes and general liability under some of its agreements. The Company has entered into certain insurance contracts that may limit its exposure to such indemnifications. As of March 30, 2014, the Company had not recorded any liability in connection with these indemnifications, as it does not believe, based on information available, that it is probable that any amounts will be paid under these guarantees.
	Generally, the Company indemnifies, under pre-determined conditions and limitations, its customers for infringement of third-party intellectual property rights by the Company’s products or services. The Company seeks to limit its liability for such indemnity to an amount not to exceed the sales price of the products or services subject to its indemnification obligations. The Company does not believe, based on information available, that it is probable that any material amounts will be paid under these guarantees.
	The Company provides guarantees and standby letters of credit to certain parties as required for certain transactions initiated during the ordinary course of business. As of March 30, 2014, the maximum potential amount of future payments that we could be required to make under these arrangements and letters of credit was $20.9 million. We do not believe, based on historical experience and information currently available, that it is probable that any amounts will be required to be paid.
	Warranties
	The Company provides standard warranties on its systems. The liability amount is based on actual historical warranty spending activity by type of system, customer, and geographic region, modified for any known differences such as the impact of system reliability improvements.

	Changes in the Company’s product warranty reserves were as follows:


		Three Months Ended						Nine Months Ended
		March 30,			March 31,			March 30,			March 31,
		2014			2013			2014			2013
		(in thousands)
	Balance at beginning of period	$	67,413		$	62,922		$	58,078		$	70,161
	Warranties issued during the period		25,106			18,829			67,405			53,377
	Settlements made during the period		(19,686	)		(27,101	)		(52,958	)		(72,960	)
	Changes in liability for pre-existing warranties		(258	)		90			50			4,162

	Balance at end of period	$	72,575		$	54,740		$	72,575		$	54,740

RESTRUCTURING_AND_IMPAIRMENTS

RESTRUCTURING AND IMPAIRMENTS	9 Months Ended
RESTRUCTURING AND IMPAIRMENTS	Mar. 30, 2014
RESTRUCTURING AND IMPAIRMENTS	'
	NOTE 15 — RESTRUCTURING AND IMPAIRMENTS
	From time to time, the Company initiates restructuring activities to appropriately align its cost structure relative to prevailing economic and industry conditions and associated customer demand as well as in connection with certain acquisitions. Costs associated with restructuring actions can include termination benefits and related charges in addition to facility closure, contract termination and other related activities.
	Accounting for restructuring activities, as compared to regular operating cost management activities, requires an evaluation of formally committed and approved plans. Restructuring activities have comparatively greater strategic significance and materiality and may involve exit activities, whereas regular cost containment activities are more tactical in nature and are rarely characterized by formal and integrated action plans or exiting a particular product, facility, or service.
	March 2009 Plan
	Beginning in the March 2009 quarter, the Company incurred restructuring expenses designed to align the Company’s cost structure with its outlook for the economic environment and business opportunities. During the March 2014 quarter, the Company entered into the Operating Leases and de-recognized the remaining liability associated with the residual value guarantee. See Note 14 to the Condensed Consolidated Financial Statements for additional information regarding residual value guarantees.
	Acquired Restructuring Liabilities
	In addition to restructuring plans initiated by the Company, a restructuring liability related to future rent obligations on unoccupied facilities was assumed in the Novellus acquisition. The associated liability balance of $10.3 million, as of March 30, 2014, is expected to be paid by the end of fiscal year 2017.

STOCK_REPURCHASE_PROGRAM

STOCK REPURCHASE PROGRAM	9 Months Ended
STOCK REPURCHASE PROGRAM	Mar. 30, 2014
STOCK REPURCHASE PROGRAM	'
	NOTE 16 — STOCK REPURCHASE PROGRAM
	On April 22, 2013, the Board of Directors authorized the repurchase of up to $250 million of Common Stock. In addition, on April 29, 2014, the Board of Directors authorized the repurchase of up to $850 million of Common Stock, which includes the remaining value available under the Company’s prior authorization. These repurchases can be conducted on the open market or as private purchases and may include the use of derivative contracts with large financial institutions, in all cases subject to compliance with applicable law. Repurchases will be funded using the Company’s on-shore cash and on-shore cash generation. This repurchase program has no termination date and may be suspended or discontinued at any time.
	Repurchases under the 2013 repurchase program were as follows during the periods indicated:


	Period		Total Number of		Total Cost of		Average Price Paid		Amount Available
			Shares Repurchased		Repurchase		Per Share*		Under Repurchase
									Program
			(in thousands, except per share data)
	Available balance as of June 30, 2013								$	250,000
	Quarter ended September 29, 2013			1,935	$	96,462	$	48.06	$	153,538
	Quarter ended December 29, 2013			762	$	39,800	$	52.2	$	113,738
	Quarter ended March 30, 2014			930	$	49,414	$	53.13	$	64,324

	*	Average price paid per share excludes accelerated share repurchases for which cost was incurred during the September 2013 quarter, but that did not settle until the December 2013 quarter. See Collared Accelerated Share Repurchases section below for details regarding average price associated with these transactions.
	In addition to shares repurchased under the Board-authorized repurchase program shown above, during the nine months ended March 30, 2014, the Company acquired 468,585 shares at a total cost of $23.9 million, which the Company withheld through net share settlements to cover minimum tax withholding obligations upon the vesting of restricted stock unit awards granted under the Company’s equity compensation plans. The shares retained by the Company through these net share settlements are not a part of the Board-authorized repurchase program but instead are authorized under the Company’s equity compensation plans.
	As part of its share repurchase program, the Company may from time-to-time enter into structured share repurchase arrangements with financial institutions using general corporate funds. Such arrangements entered into or settled during the nine months ended March 30, 2014 included the following:
	Collared Accelerated Share Repurchases
	During the nine months ended March 30, 2014, the Company entered into a collared accelerated share repurchase (“ASR”) transaction under a master repurchase arrangement. Under the ASR, the Company made an up-front cash payment of $75 million, in exchange for an initial delivery of 1.2 million shares of its Common Stock and a subsequent delivery of 0.3 million shares following the initial hedge period.
	The number of shares to ultimately be repurchased by the Company is based generally on the volume-weighted average price (“VWAP”) of the Common Stock during the term of the ASR minus a pre-determined discount set at inception of the ASR, subject to collar provisions that provide a minimum and maximum number of shares that the Company could repurchase under the agreements. The minimum and maximum thresholds for the transaction were established based on the average of the VWAP prices for the Common Stock during an initial hedge period. The ASR was scheduled to end at any time after September 27, 2013 and on or before November 27, 2013. At the conclusion of the ASR, the Company may receive additional shares based on the VWAP of the Common Stock during the term of the agreement minus the pre-determined fixed discount, however, the total number of shares received under the ASR would not exceed the maximum of 1.7 million shares.
	The counterparty designated October 28, 2013 as the termination date, at which time the Company settled the ASR. No additional shares were received at final settlement, which represented a weighted-average share price of approximately $50.40 for the transaction period.
	The Company accounted for the ASR as two separate transactions: (a) as shares of Common Stock acquired in a treasury stock transaction recorded on the acquisition date and (b) as a forward contract indexed to the Company’s own Common Stock and classified in stockholders’ equity. As such, the Company accounted for the shares that it received under the ASR as a repurchase of its Common Stock for the purpose of calculating earnings per common share. The Company has determined that the forward contract indexed to the Common Stock met all of the applicable criteria for equity classification in accordance with the Derivatives and Hedging topic of the FASB Accounting Standards Codification, and, therefore, the ASR was not accounted for as a derivative instrument. As of March 30, 2014, the aggregate repurchase price of $75 million was reflected as Treasury stock, at cost, in the Consolidated Balance Sheet.

LEGAL_PROCEEDINGS

LEGAL PROCEEDINGS	9 Months Ended
LEGAL PROCEEDINGS	Mar. 30, 2014
LEGAL PROCEEDINGS	'
	NOTE 17 — LEGAL PROCEEDINGS
	The Company is either a defendant or plaintiff in various actions that have arisen from time to time in the normal course of business, including intellectual property claims. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company believes that the amount of any such additional loss would be immaterial to the Company’s business, financial condition, and results of operations.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Mar. 30, 2014
SUBSEQUENT EVENTS	'
	NOTE 18 — SUBSEQUENT EVENTS
	On April 29, 2014 our Board of Directors announced its plan to initiate a quarterly dividend, and declared a dividend of $0.18 per share payable on July 2, 2014 to stockholders of record as of June 11, 2014. Our ability to pay future quarterly dividends will be subject to capital availability and periodic determinations by our Board of Directors that cash dividends are in the best interest of our stockholders and are in compliance with all laws and agreements applicable to the declaration and payment of cash dividends by us.
	In addition, on April 29, 2014 our Board of Directors has authorized the repurchase of up to $850 million of common stock, which includes the remaining value available under the Company’s prior authorization.

EQUITYBASED_COMPENSATION_PLANS1

EQUITY-BASED COMPENSATION PLANS (Tables)	9 Months Ended
EQUITY-BASED COMPENSATION PLANS (Tables)	Mar. 30, 2014
Recognized Equity Based Compensation Expenses and Related Income Tax Benefit	'
	The Company recognized the following equity-based compensation expense and related income tax benefit in the Condensed Consolidated Statements of Operations:


		Three Months Ended						Nine Months Ended
		March 30,			March 31,			March 30,		March 31,
		2014			2013			2014		2013
		(in millions)
	Equity-based compensation expense	$	24.3		$	25.6		$	70.6	$	74.1
	Income tax benefit related to equity-based compensation expense	$	4.1		$	4.3		$	11.7	$	13.3
Summary of Stock Option Activity	'
	A summary of stock option activity under the Plans as of March 30, 2014 and changes during the nine months then ended is presented below:


	Options	Shares			Weighted-			Weighted-Average		Aggregate Intrinsic
		(in thousands)			Average			Remaining		Value as of
					Exercise Price			Contractual Term		March 30, 2014
								(years)		(in thousands)
	Outstanding at June 30, 2013		2,571		$	26.87			4.48
	Granted		166		$	51.76
	Exercised		(1,065	)	$	24.5
	Forfeited or expired		(1	)	$	29.71

	Outstanding at March 30, 2014		1,671		$	30.86			4.78	$	39,501

	Exercisable at March 30, 2014		1,066		$	24.62			3.86	$	31,840

Summary of Restricted Stock Units	'
	A summary of the Company’s RSUs as of March 30, 2014 and changes during the nine months then ended is presented below:


		Shares			Average Grant-
	Unvested Restricted Stock Units	(in thousands)			Date Fair Value
	Unvested at June 30, 2013		4,842		$	39.32
	Granted		1,376		$	49.47
	Vested		(1,313	)	$	39.84
	Forfeited		(181	)	$	39.48

	Unvested at March 30, 2014		4,724		$	42.12

Schedule of ESPP Weighted-Average Assumptions	'
	Purchase rights under the 1999 ESPP were valued using the Black-Scholes option valuation model assuming no expected dividends and the following weighted-average assumptions for the three and nine months ended March 30, 2014:


		Three Months Ended			Nine Months Ended
		March 30,			March 30,
		2014			2014
	Expected term (years)		0.51			0.68
	Expected stock price volatility		28.89	%		30.24	%
	Risk-free interest rate		0.09	%		0.07	%

FINANCIAL_INSTRUMENTS_Tables

FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
FINANCIAL INSTRUMENTS (Tables)	Mar. 30, 2014
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis at March 30, 2014:


						Fair Value Measurement at March 30, 2014
						Quoted Prices in								Significant
						Active Markets for				Significant Other				Unobservable
						Identical Assets				Observable Inputs				Inputs
		Total				(Level 1)				(Level 2)				(Level 3)
		(In thousands)
	Assets
	Short-Term Investments
	Money Market Funds	$	1,042,596			$	1,042,596			$	—			$	—
	Municipal Notes and Bonds		248,949				—				248,949				—
	US Treasury and Agencies		182,967				182,967				—				—
	Government-Sponsored Enterprises		41,089				—				41,089				—
	Foreign Government Bonds		34,988				—				34,988				—
	Corporate Notes and Bonds		961,378				132,549				828,829				—
	Mortgage Backed Securities - Residential		26,580				—				26,580				—
	Mortgage Backed Securities - Commercial		104,857				—				104,857				—

	Total Short-Term Investments	$	2,643,404			$	1,358,112			$	1,285,292			$	—
	Mutual Funds		28,559				28,559				—				—
	Derivative Assets		2,487				—				2,487				—

	Total Assets	$	2,674,450			$	1,386,671			$	1,287,779			$	—

	Liabilities
	Derivative Liabilities	$	1,340			$	—			$	1,190			$	150

	The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2013:


						Fair Value Measurement at June 30, 2013
		Total				Quoted Prices in				Significant Other				Significant
						Active Markets for				Observable Inputs				Unobservable
						Identical Assets				(Level 2)				Inputs
						(Level 1)								(Level 3)
		(In thousands)
	Assets
	Short-Term Investments
	Money Market Funds	$	725,311			$	725,311			$	—			$	—
	Municipal Notes and Bonds		268,746				—				268,746				—
	US Treasury and Agencies		155,293				155,293				—				—
	Government-Sponsored Enterprises		54,805				—				54,805				—
	Foreign Government Bond		24,972				—				24,972				—
	Corporate Notes and Bonds		860,492				164,885				695,607				—
	Mortgage Backed Securities - Residential		27,365				—				27,365				—
	Mortgage Backed Securities - Commercial		107,958				—				107,958				—

	Total Short-Term Investments	$	2,224,942			$	1,045,489			$	1,179,453			$	—
	Equities		7,096				7,096				—				—
	Mutual Funds		18,216				18,216				—				—
	Derivative Assets		4,929				—				4,929				—

	Total Assets	$	2,255,183			$	1,070,801			$	1,184,382			$	—

	Liabilities
	Derivative Liabilities	$	1,815			$	—			$	1,620			$	195

Schedule of Assets and Liabilities Measured at Fair Value as Reported in Consolidated Balance Sheet	'
	The amounts in the table above are reported in the Consolidated Balance Sheet as of March 30, 2014 as follows:


	Reported Within:	Total				Level 1				Level 2				Level 3
		(In thousands)
	Cash Equivalents	$	1,042,596			$	1,042,596			$	—			$	—
	Short-Term Investments		1,462,171				176,879				1,285,292				—
	Restricted Cash and Investments		138,637				138,637				—				—
	Prepaid Expenses and Other Current Assets		2,487				—				2,487				—
	Other Assets		28,559				28,559				—				—

	Total Assets	$	2,674,450			$	1,386,671			$	1,287,779			$	—

	Accrued Expenses and Other Current Liabilities	$	1,190			$	—			$	1,190			$	—
	Other Non-current Liabilities		150				—				—				150

	Total Liabilities	$	1,340			$	—			$	1,190			$	150


	The amounts in the table above are reported in the Consolidated Balance Sheet as of June 30, 2013 as follows:


	Reported Within:	Total				Level 1				Level 2				Level 3
		(In thousands)
	Cash Equivalents	$	725,311			$	725,311			$	—			$	—
	Short-Term Investments		1,334,746				155,293				1,179,453				—
	Restricted Cash and Investments		164,885				164,885				—				—
	Prepaid Expenses and Other Current Assets		4,929				—				4,929				—
	Other Assets		25,312				25,312				—				—

	Total Assets	$	2,255,183			$	1,070,801			$	1,184,382			$	—

	Accrued Expenses and Other Current Liabilities	$	1,620			$	—			$	1,620			$	—
	Other Non-current Liabilities		195				—				—				195

	Total Liabilities	$	1,815			$	—			$	1,620			$	195

Summary of Investments	'
	The following tables summarize the Company’s investments:


		March 30, 2014																June 30, 2013
		Cost				Unrealized				Unrealized				Fair Value				Cost			Unrealized			Unrealized			Fair Value
		Cost				Gain				(Loss)				Fair Value				Cost			Gain			Loss			Fair Value
		(In thousands)																(In thousands)
	Cash	$	254,982			$	—			$	—			$	254,982			$	438,813		$	—		$	—		$	438,813
	Fixed Income Money Market Funds		1,042,596				—				—				1,042,596				725,311			—			—			725,311
	Municipal Notes and Bonds		248,050				927				(28	)			248,949				268,390			805			(449	)		268,746
	US Treasury and Agencies		183,072				61				(166	)			182,967				155,648			18			(373	)		155,293
	Government-Sponsored Enterprises		41,068				51				(30	)			41,089				54,835			65			(95	)		54,805
	Foreign Government Bonds		34,979				95				(86	)			34,988				24,950			47			(25	)		24,972
	Corporate Notes and Bonds		960,356				1,771				(749	)			961,378				861,109			1,328			(1,945	)		860,492
	Mortgage Backed Securities - Residential		26,802				30				(252	)			26,580				27,618			29			(282	)		27,365
	Mortgage Backed Securities - Commercial		105,264				141				(548	)			104,857				108,204			426			(672	)		107,958

	Total Cash and Short -Term Investments	$	2,897,169			$	3,076			$	(1,859	)		$	2,898,386			$	2,664,878		$	2,718		$	(3,841	)	$	2,663,755

	Publicly Traded Equity Security	$	—			$	—			$	—			$	—			$	5,610		$	1,486		$	—		$	7,096
	Private Equity Security		—				—				—				—				5,000			—			—			5,000
	Mutual Funds		25,656				2,903				—				28,559				16,611			1,619			(14	)		18,216

	Total Financial Instruments	$	2,922,825			$	5,979			$	(1,859	)		$	2,926,945			$	2,692,099		$	5,823		$	(3,855	)	$	2,694,067

	Reported Within
	Cash and Cash Equivalents	$	1,292,301			$	—			$	—			$	1,292,301			$	1,162,473		$	—		$	—		$	1,162,473
	Short-Term Investments		1,460,954				3,076				(1,859	)			1,462,171				1,335,868			2,718			(3,841	)		1,334,745
	Restricted Cash and Investments		143,914				—				—				143,914				166,536			—			—			166,536
	Other assets		25,656				2,903				—				28,559				27,222			3,105			(14	)		30,313

	Total	$	2,922,825			$	5,979			$	(1,859	)		$	2,926,945			$	2,692,099		$	5,823		$	(3,855	)	$	2,694,067

Schedule of Fixed Income Securities in Unrealized Loss Positions	'
	The following is an analysis of the Company’s fixed income securities in unrealized loss positions:


		March 30, 2014
		Unrealized Losses								Unrealized Losses
		Less Than 12 Months								12 Months or Greater								Total
		Fair Value				Gross				Fair Value				Gross				Fair Value			Gross
						Unrealized								Unrealized							Unrealized
						Loss								Loss							Loss
		(In thousands)
	Short-Term Investments
	Municipal Notes and Bonds	$	17,114			$	(28	)		$	—			$	—			$	17,114		$	(28	)
	US Treasury and Agencies		96,394				(166	)			—				—				96,394			(166	)
	Government-Sponsored Enterprises		14,071				(30	)			—				—				14,071			(30	)
	Foreign Government Bonds		18,487				(86	)			—				—				18,487			(86	)
	Corporate Notes and Bonds		261,299				(729	)			6,465				(20	)			267,764			(749	)
	Mortgage Backed Securities - Residential		20,974				(243	)			127				(9	)			21,101			(252	)
	Mortgage Backed Securities - Commercial		75,081				(404	)			4,249				(144	)			79,330			(548	)

	Total Short-Term Investments	$	503,420			$	(1,686	)		$	10,841			$	(173	)		$	514,261		$	(1,859	)

Schedule of Amortized Cost and Fair Value of Cash Equivalents, Short-Term Investments, and Restricted Cash and Investments with Contractual Maturities	'
	The amortized cost and fair value of cash equivalents, short-term investments, and restricted cash and investments with contractual maturities are as follows as of March 30, 2014:


		Cost				Estimated Fair
		Cost				Value
		(in thousands)
	Due in one year or less	$	1,316,589			$	1,317,140
	Due after one year through five years		1,035,559				1,036,852
	Due in more than five years		290,039				289,412

		$	2,642,187			$	2,643,404

Schedule of Outstanding Foreign Currency Forward Contracts	'
	As of March 30, 2014, the Company had the following outstanding foreign currency forward contracts that were entered into under its cash flow and balance sheet hedge program:


		Derivatives Designated as								Derivatives Not Designated as
		Hedging Instruments:								Hedging Instruments:
		(in thousands)
	Foreign Currency Forward Contracts
		Buy Contracts				Sell Contracts				Buy Contracts				Sell Contracts
	Japanese Yen	$	—			$	123,282			$	—			$	65,959
	Swiss Franc										7,496				—
	Euro		60,487				—				—				8,901
	Korean Won		—				—				36,386				—
	Taiwan Dollar		—				—				188,583				65,899

		$	60,487			$	123,282			$	232,465			$	140,759

Schedule of Fair Value of Derivatives Instruments	'
	The fair value of derivative instruments in the Company’s Consolidated Balance Sheets as of March 30, 2014 and June 30, 2013 were as follows:


		March 30, 2014												June 30, 2013
		Fair Value of Derivative Instruments												Fair Value of Derivative Instruments
		Asset Derivatives						Liability Derivatives						Asset Derivatives						Liability Derivatives
		Balance Sheet		Fair Value				Balance Sheet		Fair Value				Balance Sheet		Fair Value				Balance Sheet	Fair
		Location		Fair Value				Location		Fair Value				Location		Fair Value				Location	Value
		(in thousands)
	Derivatives designated as hedging instruments:
	Foreign exchange forward contracts	Prepaid expense and other assets		$	2,297			Accrued liabilities		$	619			Prepaid expense and other assets		$	4,858			Accrued	$	1,577
	Foreign exchange forward contracts	Prepaid expense and other assets		$	2,297			Accrued liabilities		$	619			Prepaid expense and other assets		$	4,858			liabilities	$	1,577
	Derivatives not designated as hedging instruments:
	Foreign exchange forward contracts	Prepaid expense and other assets			190			Accrued liabilities			571			Prepaid expense and other assets			71			Accrued		43
	Foreign exchange forward contracts	Prepaid expense and other assets			190			Accrued liabilities			571			Prepaid expense and other assets			71			liabilities		43

	Total derivatives			$	2,487					$	1,190					$	4,929				$	1,620

Schedule of Derivative Instruments Designated as Cash Flow Hedges in Statements of Operations Including Accumulated Other Comprehensive Income ("AOCI")	'
	The effect of derivative instruments designated as cash flow hedges on the Company’s Condensed Consolidated Statements of Operations, including accumulated other comprehensive income (“AOCI”) was as follows:


		Three Months Ended March 30, 2014												Nine Months Ended March 30, 2014
		Effective Portion								Ineffective Portion and				Effective Portion							Ineffective Portion and
										Amount Excluded from											Amount Excluded from
										Effectiveness Testing											Effectiveness Testing
	Location of Gain (Loss) Recognized in or	Gain (Loss)				Gain				Gain (Loss)				Gain				Gain			Gain (Loss)
	Reclassified into Income	Recognized				Reclassified				Recognized				Recognized				Reclassified			Recognized
		in AOCI				from AOCI				in Income				in AOCI				from AOCI			in Income
						into Income												into Income
		(in thousands)												(in thousands)
	Revenue	$	(621	)		$	2,787			$	54			$	7,483			$	8,947		$	232
	Cost of goods sold		307				646				(10	)			1,717				1,764			(66	)
	Selling, general, and administrative		112				291				(5	)			667				800			(29	)
	Other income (expense)		—				—				—				—				—			—

		$	(202	)		$	3,724			$	39			$	9,867			$	11,511		$	137


		Three Months Ended March 31, 2013												Nine Months Ended March 31, 2013
		Effective Portion								Ineffective Portion and				Effective Portion							Ineffective Portion and
										Amount Excluded from											Amount Excluded from
										Effectiveness Testing											Effectiveness Testing
	Location of Gain (Loss) Recognized in or	Gain (Loss)				Gain				Gain (Loss)				Gain				Gain (Loss)			Gain (Loss)
	Reclassified into Income	Recognized				Reclassified				Recognized				Recognized				Reclassified			Recognized
		in AOCI				from AOCI				in Income				in AOCI				from AOCI			in Income
						into Income												into Income
		(in thousands)												(in thousands)
	Revenue	$	9,454			$	3,850			$	78			$	8,159			$	4,574		$	274
	Cost of goods sold		(563	)			1,194				(44	)			1,332				(1,069	)		(208	)
	Selling, general, and administrative		(491	)			345				(20	)			537				(405	)		(100	)
	Other income (expense)		—				—				—				—				—			(8	)

		$	8,400			$	5,389			$	14			$	10,028			$	3,100		$	(42	)

	The effect of derivative instruments not designated as cash flow hedges on the Company’s Condensed Consolidated Statements of Operations was as follows:


				Three Months Ended								Nine Months Ended
				March 30, 2014				March 31, 2013				March 30, 2014				March 31, 2013
	Derivatives Not Designated	Location of Gain (Loss) Recognized in		Loss				Gain				Gain				Gain
	as Hedging Instruments:	Income		Recognized				Recognized				Recognized				Recognized
				in Income				in Income				in Income				in Income
				(in thousands)
	Foreign Exchange Contracts	Other income (expense)		$	(6,527	)		$	2,061			$	4,512			$	2,347

INVENTORIES_Tables

INVENTORIES (Tables)	9 Months Ended
INVENTORIES (Tables)	Mar. 30, 2014
Schedule of Inventories	'
	Inventories consist of the following:


		March 30,		June 30,
		2014		2013
		(in thousands)
	Raw materials	$	440,772	$	312,484
	Work-in-process		114,890		101,530
	Finished goods		161,694		145,303

		$	717,356	$	559,317

PROPERTY_AND_EQUIPMENT_NET_Tab

PROPERTY AND EQUIPMENT, NET (Tables)	9 Months Ended
PROPERTY AND EQUIPMENT, NET (Tables)	Mar. 30, 2014
Schedule of Property and Equipment Net	'
	Property and equipment, net, consists of the following:


		March 30,			June 30,
		2014			2013
		(in thousands)
	Manufacturing, engineering and office equipment	$	590,505		$	521,047
	Computer equipment and software		128,753			120,144
	Land		55,951			65,360
	Buildings		207,537			249,126
	Leasehold improvements		79,152			76,225
	Furniture and fixtures		24,824			21,110

			1,086,722			1,053,012
	Less: accumulated depreciation and amortization		(534,131	)		(449,102	)

		$	552,591		$	603,910

GOODWILL_AND_INTANGIBLE_ASSETS1

GOODWILL AND INTANGIBLE ASSETS (Tables)	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS (Tables)	Mar. 30, 2014
Schedule of Finite-Lived Intangible Assets	'
	The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of March 30, 2014:


		Gross		Accumulated			Net		Weighted-Average
		Gross		Amortization			Net		Useful Life
		(in thousands)							(years)
	Customer relationships	$	625,072	$	(156,121	)	$	468,951		9.01
	Existing technology		662,357		(207,981	)		454,376		6.96
	Patents		32,053		(23,887	)		8,166		6.09
	Other intangible assets		35,216		(35,216	)		—		4.1

	Intangible assets subject to amortization		1,354,698		(423,205	)		931,493
	In process research and development		11,000					11,000
	Development rights		9,100					9,100

	Intangible assets not subject to amortization		20,100					20,100

	Total intangible assets	$	1,374,798	$	(423,205	)	$	951,593

	The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of June 30, 2013 (in thousands, except years):


		Gross		Accumulated			Net		Weighted-Average
		Gross		Amortization			Net		Useful Life
		(in thousands)							(years)
	Customer relationships	$	624,686	$	(103,519	)	$	521,167		9.01
	Existing technology		653,628		(139,894	)		513,734		6.97
	Patents		32,053		(22,036	)		10,017		6.09
	Backlog		10,000		(10,000	)		—		1
	Other intangible assets		35,216		(34,889	)		327		4.1

	Intangible assets subject to amortization		1,355,583		(310,338	)		1,045,245
	In process research and development		20,000					20,000
	Development rights		9,100					9,100

	Intangible assets not subject to amortization		29,100					29,100

	Total intangible assets	$	1,384,683	$	(310,338	)	$	1,074,345

Schedule of Indefinite-Lived Intangible Assets	'
	The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of March 30, 2014:


		Gross		Accumulated			Net		Weighted-Average
		Gross		Amortization			Net		Useful Life
		(in thousands)							(years)
	Customer relationships	$	625,072	$	(156,121	)	$	468,951		9.01
	Existing technology		662,357		(207,981	)		454,376		6.96
	Patents		32,053		(23,887	)		8,166		6.09
	Other intangible assets		35,216		(35,216	)		—		4.1

	Intangible assets subject to amortization		1,354,698		(423,205	)		931,493
	In process research and development		11,000					11,000
	Development rights		9,100					9,100

	Intangible assets not subject to amortization		20,100					20,100

	Total intangible assets	$	1,374,798	$	(423,205	)	$	951,593

	The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of June 30, 2013 (in thousands, except years):


		Gross		Accumulated			Net		Weighted-Average
		Gross		Amortization			Net		Useful Life
		(in thousands)							(years)
	Customer relationships	$	624,686	$	(103,519	)	$	521,167		9.01
	Existing technology		653,628		(139,894	)		513,734		6.97
	Patents		32,053		(22,036	)		10,017		6.09
	Backlog		10,000		(10,000	)		—		1
	Other intangible assets		35,216		(34,889	)		327		4.1

	Intangible assets subject to amortization		1,355,583		(310,338	)		1,045,245
	In process research and development		20,000					20,000
	Development rights		9,100					9,100

	Intangible assets not subject to amortization		29,100					29,100

	Total intangible assets	$	1,384,683	$	(310,338	)	$	1,074,345

Estimated Future Amortization Expense of Intangible Assets	'
	The estimated future amortization expense of purchased intangible assets as of March 30, 2014 is as follows:


	Fiscal Year	Amount
		(in thousands)
	2014 (3 months)	$	39,842
	2015		159,718
	2016		157,510
	2017		155,790
	2018		154,625
	Thereafter		264,008

		$	931,493

ACCRUED_EXPENSES_AND_OTHER_CUR1

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	Mar. 30, 2014
Schedule of Accrued Expenses and Other Current Liabilities	'
	Accrued expenses and other current liabilities consist of the following:


		March 30,		June 30,
		2014		2013
		(in thousands)
	Accrued compensation	$	283,594	$	254,795
	Warranty reserves		71,489		52,252
	Income and other taxes payable		51,178		39,420
	Other		109,243		118,061

		$	515,504	$	464,528

OTHER_EXPENSE_NET_Tables

OTHER EXPENSE, NET (Tables)	9 Months Ended
OTHER EXPENSE, NET (Tables)	Mar. 30, 2014
Components of Other Expense Net	'
	The significant components of other expense, net, are as follows:


		Three Months Ended						Nine Months Ended
		March 30,			March 31,			March 30,			March 31,
		2014			2013			2014			2013
		(in thousands)
	Interest income	$	3,110		$	3,235		$	8,661		$	11,411
	Interest expense		(15,621	)		(15,175	)		(46,220	)		(45,294	)
	Gains on deferred compensation plan related assets		3,137			3,112			8,534			7,087
	Foreign exchange gains (losses)		(85	)		(1,294	)		(181	)		(4,936	)
	Other, net		(396	)		(5,712	)		1,252			(7,430	)

		$	(9,855	)	$	(15,834	)	$	(27,954	)	$	(39,162	)

NET_INCOME_PER_SHARE_Tables

NET INCOME PER SHARE (Tables)	9 Months Ended
NET INCOME PER SHARE (Tables)	Mar. 30, 2014
Schedule of Numerators and Denominators of Basic and Diluted Computations for Net Income Per Share	'
	The following table reconciles the numerators and denominators of the basic and diluted computations for net income per share.


		Three Months Ended				Nine Months Ended
		March 30,		March 31,		March 30,		March 31,
		2014		2013		2014		2013
		(in thousands, except per share data)
	Numerator:
	Net income	$	164,396	$	18,996	$	398,894	$	28,172

	Denominator:
	Basic average shares outstanding		162,238		163,034		161,904		171,016
	Effect of potential dilutive securities:
	Employee stock plans		2,641		2,729		2,810		2,390
	Convertible notes		6,757		2,741		6,337		900

	Diluted average shares outstanding		171,636		168,504		171,051		174,306

	Net income per share - basic	$	1.01	$	0.12	$	2.46	$	0.16

	Net income per share - diluted	$	0.96	$	0.11	$	2.33	$	0.16

Schedule of Potentially Dilutive Securities Excluded from EPS Calculations	'
	The following potentially dilutive securities were excluded:


		Three Months Ended				Nine Months Ended
		March 30,		March 31,		March 30,		March 31,
		2014		2013		2014		2013
		(in thousands)
	Number of potential dilutive securities excluded		75		298		85		567

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	9 Months Ended
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)	Mar. 30, 2014
Components of Accumulated Other Comprehensive Income or Loss	'
	The components of accumulated other comprehensive income (loss), net of tax at the end of the period, as well as the activity during the period, were as follows:


			Accumulated			Accumulated			Accumulated			Accumulated			Total
			foreign			unrealized			unrealized			unrealized
			currency			holding gain			holding gain			components
			translation			(loss) on cash			(loss) on			of defined
			adjustment			flow hedges			available-for-sale			benefit plans
									investments
			(in thousands)
	Balance as of June 30, 2013		$	(17,178	)	$	2,822		$	(15	)	$	(14,322	)	$	(28,693	)
	Other comprehensive income before reclassifications			1,680			8,632			962			534			11,808
	Gains reclassified from accumulated other comprehensive income to net income			—			(10,066	) (1)		(120	) (2)		—			(10,186	)

	Net current-period other comprehensive income		$	1,680		$	(1,434	)	$	842		$	534		$	1,622

	Balance as of March 30, 2014		$	(15,498	)	$	1,388		$	827		$	(13,788	)	$	(27,071	)


	-1	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in revenue: $7,961, cost of goods sold: $1,505 and selling, general and administrative expenses: $600.
	-2	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in other expense, net.

LONGTERM_DEBT_AND_OTHER_BORROW1

LONG-TERM DEBT AND OTHER BORROWINGS (Tables)	9 Months Ended
LONG-TERM DEBT AND OTHER BORROWINGS (Tables)	Mar. 30, 2014
Schedule of Carrying Value of Convertible Senior Notes and Other Long-Term Debt	'
	The following table reflects the carrying value of the Company’s convertible senior notes and other long-term debt as of March 30, 2014 and June 30, 2013:


		March 30,			June 30,
		2014			2013
		(in millions)
	0.50% Notes due 2016	$	450		$	450
	Less: Unamortized interest discount		(34.3	)		(45.7	)

	Net carrying amount of 0.50% Notes due 2016		415.7			404.3

	1.25% Notes due 2018		450			450
	Less: Unamortized interest discount		(66.3	)		(76.9	)

	Net carrying amount of 1.25% Notes due 2018		383.7			373.1

	2.625% Notes due 2041		699.9			699.9
	Less: Unamortized interest discount		(184.2	)		(186.9	)

	Net carrying amount of 2.625% Notes due 2041		515.7			513

	Total debt		1,315.10			1,290.40

	Less: current portion of debt		(515.7	)		(513.0	)

	Long-term debt	$	799.4		$	777.4

Schedule of Recognized Interest Cost Relating to Both Contractual Interest Coupon and Amortization of Discount on Liability Component of Notes	'
	The following table presents the amount of interest cost recognized relating to both the contractual interest coupon and amortization of the discount on the liability component of the Notes during the three and nine months ended March 30, 2014 and March 31, 2013.


		Three Months Ended						Nine Months Ended
		March 30,			March 31,			March 30,		March 31,
		2014			2013			2014		2013
		(in millions)
	Contractual interest coupon	$	6.6		$	6.6			19.7		19.7
	Amortization of interest discount		8.3			7.9			24.7		23.5
	Amortization of issuance costs		0.6			0.6			1.8		1.8

	Total interest cost recognized	$	15.5		$	15.1		$	46.2	$	45

COMMITMENTS_Tables

COMMITMENTS (Tables)	9 Months Ended
COMMITMENTS (Tables)	Mar. 30, 2014
Schedule of Changes in Product Warranty Reserves	'
	Changes in the Company’s product warranty reserves were as follows:


		Three Months Ended						Nine Months Ended
		March 30,			March 31,			March 30,			March 31,
		2014			2013			2014			2013
		(in thousands)
	Balance at beginning of period	$	67,413		$	62,922		$	58,078		$	70,161
	Warranties issued during the period		25,106			18,829			67,405			53,377
	Settlements made during the period		(19,686	)		(27,101	)		(52,958	)		(72,960	)
	Changes in liability for pre-existing warranties		(258	)		90			50			4,162

	Balance at end of period	$	72,575		$	54,740		$	72,575		$	54,740

STOCK_REPURCHASE_PROGRAM_Table

STOCK REPURCHASE PROGRAM (Tables)	9 Months Ended
STOCK REPURCHASE PROGRAM (Tables)	Mar. 30, 2014
Schedule of Repurchases under 2013 Repurchase Program	'
	Repurchases under the 2013 repurchase program were as follows during the periods indicated:


	Period		Total Number of		Total Cost of		Average Price Paid		Amount Available
			Shares Repurchased		Repurchase		Per Share*		Under Repurchase
									Program
			(in thousands, except per share data)
	Available balance as of June 30, 2013								$	250,000
	Quarter ended September 29, 2013			1,935	$	96,462	$	48.06	$	153,538
	Quarter ended December 29, 2013			762	$	39,800	$	52.2	$	113,738
	Quarter ended March 30, 2014			930	$	49,414	$	53.13	$	64,324

	*	Average price paid per share excludes accelerated share repurchases for which cost was incurred during the September 2013 quarter, but that did not settle until the December 2013 quarter. See Collared Accelerated Share Repurchases section below for details regarding average price associated with these transactions.

Equity_Based_Compensation_Plan

Equity Based Compensation Plans - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Options and restricted stock units vesting period, years	'	'	'3 years	'
The total intrinsic value of options exercised	$7.10	$8	$29.30	$12.70
Unrecognized compensation expense, stock option	5.9	'	5.9	'
Stock compensation expense	24.3	25.6	70.6	74.1
Novellus Systems Incorporated	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Options and restricted stock units vesting period, years	'	'	'4 years	'
Existing Stock Plans	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Options and RSUs issued and outstanding under stock plans	6,395,328	'	6,395,328	'
Shares available for future issuance under stock plan	11,008,283	'	11,008,283	'
Stock Options	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average remaining period for recognition, years	'	'	'1 year 8 months 12 days	'
Restricted Stock Units (RSUs)	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average remaining period for recognition, years	'	'	'1 year 10 months 24 days	'
Unrecognized compensation expense	130.3	'	130.3	'
Employee Stock Purchase Plan	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Weighted average remaining period for recognition, years	'	'	'5 months	'
Unrecognized compensation expense	5.7	'	5.7	'
Number of shares available for purchase under ESPP	8,741,208	'	8,741,208	'
ESPP purchase price per share as percentage of fair market value	'	'	85.00%	'
Performance Based Restricted Stock Units (PRSU)	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Options and RSUs issued and outstanding under stock plans	600,000	'	600,000	'
Stock compensation expense	$1.20	'	$1.20	'
Performance Based Restricted Stock Units (PRSU) \| Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Common stock to be issued, vesting percentage	'	'	0.00%	'
Performance Based Restricted Stock Units (PRSU) \| Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Common stock to be issued, vesting percentage	'	'	150.00%	'

Recognized_Equity_Based_Compen

Recognized Equity Based Compensation Expenses and Related Income Tax Benefit (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Equity-based compensation expense	$24.30	$25.60	$70.60	$74.10
Income tax benefit related to equity-based compensation expense	$4.10	$4.30	$11.70	$13.30

Summary_of_Stock_Option_Activi

Summary of Stock Option Activity (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Options	'	'
Beginning balance	2,571	'
Granted	$166	'
Exercised	-1,065	'
Forfeited or expired	-1	'
Ending balance	1,671	2,571
Exercisable	1,066	'
Weighted-Average Exercise Price	'	'
Beginning balance	$26.87	'
Granted	$51.76	'
Exercised	$24.50	'
Forfeited or expired	$29.71	'
Ending balance	$30.86	$26.87
Exercisable	$24.62	'
Weighted-Average Remaining Contractual Term (in years)	'	'
Outstanding at end of period	'4 years 9 months 11 days	'4 years 5 months 23 days
Exercisable at March 30, 2014	'3 years 10 months 10 days	'
Aggregate Intrinsic Value	'	'
Outstanding at March 30, 2014	$39,501	'
Exercisable at March 30, 2014	$31,840	'

Summary_of_Restricted_Stock_Un

Summary of Restricted Stock Units (Detail) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 30, 2014
Unvested Restricted Stock Units Weighted-Average Grant Date Fair Value	'
Granted	$166
Restricted Stock Units (RSUs)	'
Unvested Restricted Stock Units	'
Beginning balance	4,842
Granted	1,376
Vested	-1,313
Forfeited	-181
Ending balance	4,724
Unvested Restricted Stock Units Weighted-Average Grant Date Fair Value	'
Beginning of Period	$39.32
Granted	$49.47
Vested	$39.84
Forfeited	$39.48
Ending of Period	$42.12

Schedule_of_Stock_Options_Weig

Schedule of Stock Options Weighted Average Assumptions (Detail)	3 Months Ended	9 Months Ended
	Mar. 30, 2014	Mar. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected term (years)	'6 months 4 days	'8 months 5 days
Expected stock price volatility	28.89%	30.24%
Risk-free interest rate	0.09%	0.07%

Schedule_of_Financial_Assets_a

Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Financial Instruments [Line Items]	'	'
Fair value	$1,462,171	$1,334,746
Derivative Assets	2,487	4,929
Total Assets	2,674,450	2,255,183
Derivative Liabilities	1,340	1,815
Money Market Funds	'	'
Financial Instruments [Line Items]	'	'
Fair value	1,042,596	725,311
Municipal Notes And Bonds	'	'
Financial Instruments [Line Items]	'	'
Fair value	248,949	268,746
US Treasury and Agencies	'	'
Financial Instruments [Line Items]	'	'
Fair value	182,967	155,293
Government-Sponsored Enterprises	'	'
Financial Instruments [Line Items]	'	'
Fair value	41,089	54,805
Foreign Government Debt Securities	'	'
Financial Instruments [Line Items]	'	'
Fair value	34,988	24,972
Corporate Notes And Bonds	'	'
Financial Instruments [Line Items]	'	'
Fair value	961,378	860,492
Mortgage Backed Securities - Residential	'	'
Financial Instruments [Line Items]	'	'
Fair value	26,580	27,365
Mortgage Backed Securities - Commercial	'	'
Financial Instruments [Line Items]	'	'
Fair value	104,857	107,958
Publicly Traded Equity Securities	'	'
Financial Instruments [Line Items]	'	'
Fair value	'	7,096
Total Short Term Investments	'	'
Financial Instruments [Line Items]	'	'
Fair value	2,643,404	2,224,942
Mutual Funds	'	'
Financial Instruments [Line Items]	'	'
Fair value	28,559	18,216
Quoted Prices in Active Markets for Identical Assets (Level 1)	'	'
Financial Instruments [Line Items]	'	'
Fair value	176,879	155,293
Total Assets	1,386,671	1,070,801
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money Market Funds	'	'
Financial Instruments [Line Items]	'	'
Fair value	1,042,596	725,311
Quoted Prices in Active Markets for Identical Assets (Level 1) \| US Treasury and Agencies	'	'
Financial Instruments [Line Items]	'	'
Fair value	182,967	155,293
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Corporate Notes And Bonds	'	'
Financial Instruments [Line Items]	'	'
Fair value	132,549	164,885
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Publicly Traded Equity Securities	'	'
Financial Instruments [Line Items]	'	'
Fair value	'	7,096
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Total Short Term Investments	'	'
Financial Instruments [Line Items]	'	'
Fair value	1,358,112	1,045,489
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Mutual Funds	'	'
Financial Instruments [Line Items]	'	'
Fair value	28,559	18,216
Significant Other Observable Inputs (Level 2)	'	'
Financial Instruments [Line Items]	'	'
Fair value	1,285,292	1,179,453
Derivative Assets	2,487	4,929
Total Assets	1,287,779	1,184,382
Derivative Liabilities	1,190	1,620
Significant Other Observable Inputs (Level 2) \| Municipal Notes And Bonds	'	'
Financial Instruments [Line Items]	'	'
Fair value	248,949	268,746
Significant Other Observable Inputs (Level 2) \| Government-Sponsored Enterprises	'	'
Financial Instruments [Line Items]	'	'
Fair value	41,089	54,805
Significant Other Observable Inputs (Level 2) \| Foreign Government Debt Securities	'	'
Financial Instruments [Line Items]	'	'
Fair value	34,988	24,972
Significant Other Observable Inputs (Level 2) \| Corporate Notes And Bonds	'	'
Financial Instruments [Line Items]	'	'
Fair value	828,829	695,607
Significant Other Observable Inputs (Level 2) \| Mortgage Backed Securities - Residential	'	'
Financial Instruments [Line Items]	'	'
Fair value	26,580	27,365
Significant Other Observable Inputs (Level 2) \| Mortgage Backed Securities - Commercial	'	'
Financial Instruments [Line Items]	'	'
Fair value	104,857	107,958
Significant Other Observable Inputs (Level 2) \| Total Short Term Investments	'	'
Financial Instruments [Line Items]	'	'
Fair value	1,285,292	1,179,453
Significant Unobservable Inputs (Level 3)	'	'
Financial Instruments [Line Items]	'	'
Derivative Liabilities	$150	$195

Schedule_of_Assets_and_Liabili

Schedule of Assets and Liabilities Measured at Fair Value as Reported in Consolidated Balance Sheet (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash Equivalents	$1,042,596	$725,311
Short-Term Investments	1,462,171	1,334,746
Restricted Cash and Investments	138,637	164,885
Prepaid Expenses and Other Current Assets	2,487	4,929
Other Assets	28,559	25,312
Total Assets	2,674,450	2,255,183
Accrued Expenses and Other Current Liabilities	1,190	1,620
Other Non-current Liabilities	150	195
Total Liabilities	1,340	1,815
Quoted Prices in Active Markets for Identical Assets (Level 1)	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash Equivalents	1,042,596	725,311
Short-Term Investments	176,879	155,293
Restricted Cash and Investments	138,637	164,885
Other Assets	28,559	25,312
Total Assets	1,386,671	1,070,801
Significant Other Observable Inputs (Level 2)	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Short-Term Investments	1,285,292	1,179,453
Prepaid Expenses and Other Current Assets	2,487	4,929
Total Assets	1,287,779	1,184,382
Accrued Expenses and Other Current Liabilities	1,190	1,620
Total Liabilities	1,190	1,620
Significant Unobservable Inputs (Level 3)	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Other Non-current Liabilities	150	195
Total Liabilities	$150	$195

Summary_of_Investments_Detail

Summary of Investments (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Financial Instruments [Line Items]	'	'
Fair Value	$1,462,171	$1,334,746
Cash	'	'
Financial Instruments [Line Items]	'	'
Cost	254,982	438,813
Fair Value	254,982	438,813
Fixed Income Money Market Funds	'	'
Financial Instruments [Line Items]	'	'
Cost	1,042,596	725,311
Fair Value	1,042,596	725,311
Municipal Notes And Bonds	'	'
Financial Instruments [Line Items]	'	'
Cost	248,050	268,390
Unrealized Gain	927	805
Unrealized (Loss)	-28	-449
Fair Value	248,949	268,746
US Treasury and Agencies	'	'
Financial Instruments [Line Items]	'	'
Cost	183,072	155,648
Unrealized Gain	61	18
Unrealized (Loss)	-166	-373
Fair Value	182,967	155,293
Government-Sponsored Enterprises	'	'
Financial Instruments [Line Items]	'	'
Cost	41,068	54,835
Unrealized Gain	51	65
Unrealized (Loss)	-30	-95
Fair Value	41,089	54,805
Foreign Government Bonds	'	'
Financial Instruments [Line Items]	'	'
Cost	34,979	24,950
Unrealized Gain	95	47
Unrealized (Loss)	-86	-25
Fair Value	34,988	24,972
Corporate Notes And Bonds	'	'
Financial Instruments [Line Items]	'	'
Cost	960,356	861,109
Unrealized Gain	1,771	1,328
Unrealized (Loss)	-749	-1,945
Fair Value	961,378	860,492
Mortgage Backed Securities - Residential	'	'
Financial Instruments [Line Items]	'	'
Cost	26,802	27,618
Unrealized Gain	30	29
Unrealized (Loss)	-252	-282
Fair Value	26,580	27,365
Mortgage Backed Securities - Commercial	'	'
Financial Instruments [Line Items]	'	'
Cost	105,264	108,204
Unrealized Gain	141	426
Unrealized (Loss)	-548	-672
Fair Value	104,857	107,958
Total Cash And Short Term Investments	'	'
Financial Instruments [Line Items]	'	'
Cost	2,897,169	2,664,878
Unrealized Gain	3,076	2,718
Unrealized (Loss)	-1,859	-3,841
Fair Value	2,898,386	2,663,755
Publicly Traded Equity Securities	'	'
Financial Instruments [Line Items]	'	'
Cost	'	5,610
Unrealized Gain	'	1,486
Fair Value	'	7,096
Private Equity Securities	'	'
Financial Instruments [Line Items]	'	'
Cost	'	5,000
Fair Value	'	5,000
Mutual Funds	'	'
Financial Instruments [Line Items]	'	'
Cost	25,656	16,611
Unrealized Gain	2,903	1,619
Unrealized (Loss)	'	-14
Fair Value	28,559	18,216
Total Financial Instruments	'	'
Financial Instruments [Line Items]	'	'
Cost	2,922,825	2,692,099
Unrealized Gain	5,979	5,823
Unrealized (Loss)	-1,859	-3,855
Fair Value	2,926,945	2,694,067
Cash and Cash Equivalents	'	'
Financial Instruments [Line Items]	'	'
Cost	1,292,301	1,162,473
Fair Value	1,292,301	1,162,473
Short-term Investments	'	'
Financial Instruments [Line Items]	'	'
Cost	1,460,954	1,335,868
Unrealized Gain	3,076	2,718
Unrealized (Loss)	-1,859	-3,841
Fair Value	1,462,171	1,334,745
Restricted Cash And Investments	'	'
Financial Instruments [Line Items]	'	'
Cost	143,914	166,536
Fair Value	143,914	166,536
Other Assets	'	'
Financial Instruments [Line Items]	'	'
Cost	25,656	27,222
Unrealized Gain	2,903	3,105
Unrealized (Loss)	'	-14
Fair Value	28,559	30,313
Total	'	'
Financial Instruments [Line Items]	'	'
Cost	2,922,825	2,692,099
Unrealized Gain	5,979	5,823
Unrealized (Loss)	-1,859	-3,855
Fair Value	$2,926,945	$2,694,067

Financial_Instruments_Addition

Financial Instruments - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013	Jun. 30, 2013
Financial Instruments [Line Items]	'	'	'	'	'
Other than temporary impairment included in net realized gains (losses)	$0	'	$0	'	'
Gains realized from sales of investments	400,000	200,000	800,000	1,400,000	'
Losses realized from sales of investments	-700,000	-400,000	-1,700,000	-1,100,000	'
Investment classified as short term, maturity period	'1 year	'	'1 year	'	'
Gains (losses) accumulated in Other Comprehensive Income expects to reclassify from Other Comprehensive Income into earnings	1,400,000	'	1,400,000	'	'
Net derivative asset from master netting agreements	2,487,000	'	2,487,000	'	4,929,000
Foreign Exchange Forward Contracts \| Cash flow hedging	'	'	'	'	'
Financial Instruments [Line Items]	'	'	'	'	'
Potential effect of rights of set-off under master netting agreements for foreign exchange contracts assets	700,000	'	700,000	'	1,600,000
Potential effect of rights of set-off under master netting agreements for foreign exchange contracts liabilities	700,000	'	700,000	'	1,600,000
Net derivative asset from master netting agreements	1,300,000	'	1,300,000	'	3,300,000
Publicly Equity Investment	'	'	'	'	'
Financial Instruments [Line Items]	'	'	'	'	'
Other than temporary impairment included in net realized gains (losses)	'	$3,700,000	'	$3,700,000	'
Maximum	'	'	'	'	'
Financial Instruments [Line Items]	'	'	'	'	'
Foreign currency forward contract, expiration period	'	'	'24 months	'	'
Maximum \| Majority of Contracts	'	'	'	'	'
Financial Instruments [Line Items]	'	'	'	'	'
Foreign currency forward contract, expiration period	'	'	'12 months	'	'

Schedule_of_Fixed_Income_Secur

Schedule of Fixed Income Securities in Unrealized Loss Positions (Detail) (USD $)	Mar. 30, 2014
In Thousands, unless otherwise specified	Mar. 30, 2014
Schedule of Available-for-sale Securities [Line Items]	'
Unrealized Losses Less Than 12 Months - Fair Value	$503,420
Unrealized Losses Less Than 12 Months - Unrealized	-1,686
Unrealized Losses 12 Months or Greater - Fair Value	10,841
Unrealized Losses 12 Months or Greater - Unrealized	-173
Total - Fair Value	514,261
Total - Unrealized	-1,859
Municipal Notes And Bonds	'
Schedule of Available-for-sale Securities [Line Items]	'
Unrealized Losses Less Than 12 Months - Fair Value	17,114
Unrealized Losses Less Than 12 Months - Unrealized	-28
Total - Fair Value	17,114
Total - Unrealized	-28
US Treasury and Agencies	'
Schedule of Available-for-sale Securities [Line Items]	'
Unrealized Losses Less Than 12 Months - Fair Value	96,394
Unrealized Losses Less Than 12 Months - Unrealized	-166
Total - Fair Value	96,394
Total - Unrealized	-166
Government-Sponsored Enterprises	'
Schedule of Available-for-sale Securities [Line Items]	'
Unrealized Losses Less Than 12 Months - Fair Value	14,071
Unrealized Losses Less Than 12 Months - Unrealized	-30
Total - Fair Value	14,071
Total - Unrealized	-30
Foreign Government Bonds	'
Schedule of Available-for-sale Securities [Line Items]	'
Unrealized Losses Less Than 12 Months - Fair Value	18,487
Unrealized Losses Less Than 12 Months - Unrealized	-86
Total - Fair Value	18,487
Total - Unrealized	-86
Corporate Notes And Bonds	'
Schedule of Available-for-sale Securities [Line Items]	'
Unrealized Losses Less Than 12 Months - Fair Value	261,299
Unrealized Losses Less Than 12 Months - Unrealized	-729
Unrealized Losses 12 Months or Greater - Fair Value	6,465
Unrealized Losses 12 Months or Greater - Unrealized	-20
Total - Fair Value	267,764
Total - Unrealized	-749
Mortgage Backed Securities - Residential	'
Schedule of Available-for-sale Securities [Line Items]	'
Unrealized Losses Less Than 12 Months - Fair Value	20,974
Unrealized Losses Less Than 12 Months - Unrealized	-243
Unrealized Losses 12 Months or Greater - Fair Value	127
Unrealized Losses 12 Months or Greater - Unrealized	-9
Total - Fair Value	21,101
Total - Unrealized	-252
Mortgage Backed Securities - Commercial	'
Schedule of Available-for-sale Securities [Line Items]	'
Unrealized Losses Less Than 12 Months - Fair Value	75,081
Unrealized Losses Less Than 12 Months - Unrealized	-404
Unrealized Losses 12 Months or Greater - Fair Value	4,249
Unrealized Losses 12 Months or Greater - Unrealized	-144
Total - Fair Value	79,330
Total - Unrealized	($548)

Schedule_of_Amortized_Cost_and

Schedule of Amortized Cost and Fair Value of Cash Equivalents, Short-Term Investments, and Restricted Cash and Investments with Contractual Maturities (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Due in one year or less, Cost	$1,316,589	'
Due in one year or less, Estimated Fair Value	1,317,140	'
Due after one year through five years, Cost	1,035,559	'
Due after one year through five years, Estimated Fair Value	1,036,852	'
Due in more than five years, Cost	290,039	'
Due in more than five years, Estimated Fair Value	289,412	'
Cost	2,642,187	'
Estimated Fair Value	1,462,171	1,334,746
Total Short Term Investments	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Estimated Fair Value	$2,643,404	'

Schedule_of_Outstanding_Foreig

Schedule of Outstanding Foreign Currency Forward Contracts (Detail) (USD $)	Mar. 30, 2014
In Thousands, unless otherwise specified	Mar. 30, 2014
Buy Contracts	'
Derivative [Line Items]	'
Derivatives Designated as Hedging Instruments	$60,487
Derivatives Not Designated as Hedging Instruments	232,465
Buy Contracts \| Switzerland, Francs	'
Derivative [Line Items]	'
Derivatives Not Designated as Hedging Instruments	7,496
Buy Contracts \| Euro	'
Derivative [Line Items]	'
Derivatives Designated as Hedging Instruments	60,487
Buy Contracts \| Korean Won	'
Derivative [Line Items]	'
Derivatives Not Designated as Hedging Instruments	36,386
Buy Contracts \| Taiwan Dollar	'
Derivative [Line Items]	'
Derivatives Not Designated as Hedging Instruments	188,583
Sell Contracts	'
Derivative [Line Items]	'
Derivatives Designated as Hedging Instruments	123,282
Derivatives Not Designated as Hedging Instruments	140,759
Sell Contracts \| Japanese Yen	'
Derivative [Line Items]	'
Derivatives Designated as Hedging Instruments	123,282
Derivatives Not Designated as Hedging Instruments	65,959
Sell Contracts \| Euro	'
Derivative [Line Items]	'
Derivatives Not Designated as Hedging Instruments	8,901
Sell Contracts \| Taiwan Dollar	'
Derivative [Line Items]	'
Derivatives Not Designated as Hedging Instruments	$65,899

Schedule_of_Fair_Value_of_Deri

Schedule of Fair Value of Derivatives Instruments (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Asset Derivatives, Fair Value	$2,487	$4,929
Liability Derivatives, Fair Value	1,190	1,620
Derivatives Designated As Hedging Instruments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Asset Derivatives, Fair Value	2,297	4,858
Liability Derivatives, Fair Value	619	1,577
Derivatives Not Designated as Hedging Instruments	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Asset Derivatives, Fair Value	190	71
Liability Derivatives, Fair Value	$571	$43

Schedule_of_Derivative_Instrum

Schedule of Derivative Instruments Designated as Cash Flow Hedges in Statements of Operations Including Accumulated Other Comprehensive Income ("AOCI") (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Gain (Loss) Recognized in AOCI (Effective Portion)	($202)	$8,400	$9,867	$10,028
Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	3,724	5,389	11,511	3,100
Gain (Loss) Recognized (Excluded from Effectiveness Testing)	39	14	137	-42
Located in revenue	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Gain (Loss) Recognized in AOCI (Effective Portion)	-621	9,454	7,483	8,159
Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	2,787	3,850	8,947	4,574
Gain (Loss) Recognized (Excluded from Effectiveness Testing)	54	78	232	274
Located in cost of goods sold	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Gain (Loss) Recognized in AOCI (Effective Portion)	307	-563	1,717	1,332
Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	646	1,194	1,764	-1,069
Gain (Loss) Recognized (Excluded from Effectiveness Testing)	-10	-44	-66	-208
Located in selling, general, and adminstrative	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Gain (Loss) Recognized in AOCI (Effective Portion)	112	-491	667	537
Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	291	345	800	-405
Gain (Loss) Recognized (Excluded from Effectiveness Testing)	-5	-20	-29	-100
Located in other income (expense)	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Gain (Loss) Recognized (Excluded from Effectiveness Testing)	'	'	'	-8
Foreign Exchange Forward Contracts	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Gain (Loss) Recognized	($6,527)	$2,061	$4,512	$2,347

Schedule_of_Inventories_Detail

Schedule of Inventories (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Inventory [Line Items]	'	'
Raw materials	$440,772	$312,484
Work-in-process	114,890	101,530
Finished goods	161,694	145,303
Total inventories	$717,356	$559,317	[1]

[1]	Derived from audited financial statements

Schedule_of_Property_and_Equip

Schedule of Property and Equipment Net (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Line Items]	'	'
Manufacturing, engineering and office equipment	$590,505	$521,047
Computer equipment and software	128,753	120,144
Land	55,951	65,360
Buildings	207,537	249,126
Leasehold improvements	79,152	76,225
Furniture and fixtures	24,824	21,110
Property and equipment, gross	1,086,722	1,053,012
Less: accumulated depreciation and amortization	-534,131	-449,102
Property and equipment, net	$552,591	$603,910	[1]

[1]	Derived from audited financial statements

Property_and_Equipment_Net_Add

Property and Equipment, Net - Additional Information (Detail) (USD $)	Mar. 30, 2014
In Millions, unless otherwise specified	Mar. 30, 2014
Property, Plant and Equipment [Line Items]	'
Assets held-for-sale	$69

Recovered_Sheet1

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013	Jun. 30, 2013
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'
Goodwill	$1,457,320,000	'	$1,457,320,000	'	$1,452,196,000	[1]
Tax deductible goodwill	61,000,000	'	61,000,000	'	'
Intangible asset amortization expense	40,400,000	45,000,000	122,900,000	134,300,000	'
In Process Research And Development	'	'	'	'	'
Goodwill And Intangible Assets [Line Items]	'	'	'	'	'
Impairment intangible assets	'	$4,000,000	'	$4,000,000	'

[1]	Derived from audited financial statements

Schedule_of_Intangible_Assets_

Schedule of Intangible Assets (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Goodwill And Intangible Assets [Line Items]	'	'
Gross intangible assets subject to amortization	$1,354,698	$1,355,583
Total gross intangible assets	1,374,798	1,384,683
Accumulated Amortization	-423,205	-310,338
Net intangible assets subject to amortization	931,493	1,045,245
Intangible assets, net	951,593	1,074,345	[1]
Intangible assets not subject to amortization	20,100	29,100
Intangible assets not subject to amortization	20,100	29,100
In Process Research And Development	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Intangible assets not subject to amortization	11,000	20,000
Intangible assets not subject to amortization	11,000	20,000
Developed Technology Rights	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Intangible assets not subject to amortization	9,100	9,100
Intangible assets not subject to amortization	9,100	9,100
Customer Relationships	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Gross intangible assets subject to amortization	625,072	624,686
Accumulated Amortization	-156,121	-103,519
Net intangible assets subject to amortization	468,951	521,167
Weighted-Average Useful Life (years)	'9 years 4 days	'9 years 4 days
Existing Technology	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Gross intangible assets subject to amortization	662,357	653,628
Accumulated Amortization	-207,981	-139,894
Net intangible assets subject to amortization	454,376	513,734
Weighted-Average Useful Life (years)	'6 years 11 months 16 days	'6 years 11 months 19 days
Patents	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Gross intangible assets subject to amortization	32,053	32,053
Accumulated Amortization	-23,887	-22,036
Net intangible assets subject to amortization	8,166	10,017
Weighted-Average Useful Life (years)	'6 years 1 month 2 days	'6 years 1 month 2 days
Backlog	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Gross intangible assets subject to amortization	'	10,000
Accumulated Amortization	'	-10,000
Weighted-Average Useful Life (years)	'	'1 year
Other Intangible Assets	'	'
Goodwill And Intangible Assets [Line Items]	'	'
Gross intangible assets subject to amortization	35,216	35,216
Accumulated Amortization	-35,216	-34,889
Net intangible assets subject to amortization	'	$327
Weighted-Average Useful Life (years)	'4 years 1 month 6 days	'4 years 1 month 6 days

[1]	Derived from audited financial statements

Estimated_Future_Amortization_

Estimated Future Amortization Expense of Intangible Assets (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
2014 (3 months)	$39,842	'
2015	159,718	'
2016	157,510	'
2017	155,790	'
2018	154,625	'
Thereafter	264,008	'
Net intangible assets subject to amortization	$931,493	$1,045,245

Schedule_of_Accrued_Expenses_a

Schedule of Accrued Expenses and Other Current Liabilities (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013
Schedule of Accrued Liabilities [Line Items]	'	'
Accrued compensation	$283,594	$254,795
Warranty reserves	71,489	52,252
Income and other taxes payable	51,178	39,420
Other	109,243	118,061
Accrued expenses and other current liabilities	$515,504	$464,528	[1]

[1]	Derived from audited financial statements

Components_of_Other_Expense_Ne

Components of Other Expense Net (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Component Of Other Expense Income Nonoperating [Line Items]	'	'	'	'
Interest income	$3,110	$3,235	$8,661	$11,411
Interest expense	-15,621	-15,175	-46,220	-45,294
Gains on deferred compensation plan related assets	3,137	3,112	8,534	7,087
Foreign exchange gains (losses)	-85	-1,294	-181	-4,936
Other, net	-396	-5,712	1,252	-7,430
Other income (expense), net	($9,855)	($15,834)	($27,954)	($39,162)

Income_Tax_Expense_Additional_

Income Tax Expense - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Income Tax [Line Items]	'	'	'	'
Income tax (benefit) expense	$17,686	($24,011)	$34,971	($35,761)
Effective income tax rate	9.70%	'	8.10%	'
U.S. federal statutory tax rate	35.00%	'	35.00%	'

Schedule_of_Numerators_and_Den

Schedule of Numerators and Denominators of Basic and Diluted Computations for Net Income Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]	'	'	'	'
Net income	$164,396	$18,996	$398,894	$28,172
Basic average shares outstanding	162,238	163,034	161,904	171,016
Employee stock plans	2,641	2,729	2,810	2,390
Convertible notes	6,757	2,741	6,337	900
Diluted average shares outstanding	171,636	168,504	171,051	174,306
Net income per share - basic	$1.01	$0.12	$2.46	$0.16
Net income per share - diluted	$0.96	$0.11	$2.33	$0.16

Schedule_of_Potentially_Diluti

Schedule of Potentially Dilutive Securities Excluded from EPS Calculations (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Number of potential dilutive securities excluded	75	298	85	567

Components_of_Accumulated_Othe

Components of Accumulated Other Comprehensive Income or Loss (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014		Mar. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'		'
Balance as of June 30, 2013	'	'	($28,693)	[1]	'
Other comprehensive income before reclassifications	'	'	11,808		'
Gains reclassified from accumulated other comprehensive income to net income	'	'	-10,186		'
Net current-period other comprehensive income	-11,550	739	1,622		10,073
Balance as of March 30, 2014	-27,071	'	-27,071		'
Accumulated Foreign Currency Translation Adjustment	'	'	'		'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'		'
Balance as of June 30, 2013	'	'	-17,178		'
Other comprehensive income before reclassifications	'	'	1,680		'
Net current-period other comprehensive income	'	'	1,680		'
Balance as of March 30, 2014	-15,498	'	-15,498		'
Accumulated Unrealized Holding Gains (Losses) on Cash Flow Hedges	'	'	'		'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'		'
Balance as of June 30, 2013	'	'	2,822		'
Other comprehensive income before reclassifications	'	'	8,632		'
Gains reclassified from accumulated other comprehensive income to net income	'	'	-10,066	[2]	'
Net current-period other comprehensive income	'	'	-1,434		'
Balance as of March 30, 2014	1,388	'	1,388		'
Accumulated Unrealized Holding Gains (Losses) on Available-For-Sale Investments	'	'	'		'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'		'
Balance as of June 30, 2013	'	'	-15		'
Other comprehensive income before reclassifications	'	'	962		'
Gains reclassified from accumulated other comprehensive income to net income	'	'	-120	[3]	'
Net current-period other comprehensive income	'	'	842		'
Balance as of March 30, 2014	827	'	827		'
Accumulated Unrealized Components of Defined Benefit Plans	'	'	'		'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'		'
Balance as of June 30, 2013	'	'	-14,322		'
Other comprehensive income before reclassifications	'	'	534		'
Net current-period other comprehensive income	'	'	534		'
Balance as of March 30, 2014	($13,788)	'	($13,788)		'

[1]	Derived from audited financial statements
[2]	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in revenue: $7,961, cost of goods sold: $1,505 and selling, general and administrative expenses: $600.
[3]	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in other expense, net

Components_of_Accumulated_Othe1

Components of Accumulated Other Comprehensive Income or Loss (Parenthetical) (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Reclassification from accumulated other comprehensive income	$10,186
Reclassified to Revenue	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Reclassification from accumulated other comprehensive income	7,961
Reclassified to cost of goods sold	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Reclassification from accumulated other comprehensive income	1,505
Reclassified to selling, general, and administrative	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Reclassification from accumulated other comprehensive income	$600

Schedule_of_Carrying_Value_of_

Schedule of Carrying Value of Convertible Senior Notes and Other Long-Term Debt (Detail) (USD $)	Mar. 30, 2014	Jun. 30, 2013	Mar. 30, 2014	Jun. 30, 2013	31-May-11	Mar. 30, 2014	Jun. 30, 2013	31-May-11	Mar. 30, 2014	Jun. 30, 2013	Jun. 24, 2012
In Millions, unless otherwise specified	Mar. 30, 2014	Jun. 30, 2013	0.50% Notes due 2016	0.50% Notes due 2016	0.50% Notes due 2016	1.25% Notes due 2018	1.25% Notes due 2018	1.25% Notes due 2018	2.625% Notes due 2041	2.625% Notes due 2041	2.625% Notes due 2041
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Notes due	'	'	$450	$450	$450	$450	$450	$450	$699.90	$699.90	$700
Less: Unamortized interest discount	'	'	-34.3	-45.7	'	-66.3	-76.9	'	-184.2	-186.9	'
Net carrying amount of Notes	'	'	415.7	404.3	'	383.7	373.1	'	515.7	513	'
Total long-term debt	1,315.10	1,290.40	'	'	'	'	'	'	'	'	'
Less: current portion of debt	-515.7	-513	'	'	'	'	'	'	'	'	'
Long-term debt	$799.40	$777.40	'	'	'	'	'	'	'	'	'

Schedule_of_Carrying_Value_of_1

Schedule of Carrying Value of Convertible Senior Notes and Other Long-Term Debt (Parenthetical) (Detail)	9 Months Ended			9 Months Ended			9 Months Ended
	Mar. 30, 2014	Jun. 30, 2013	31-May-11	Mar. 30, 2014	Jun. 30, 2013	31-May-11	Mar. 30, 2014	Jun. 30, 2013	Jun. 24, 2012
	0.50% Notes due 2016	0.50% Notes due 2016	0.50% Notes due 2016	1.25% Notes due 2018	1.25% Notes due 2018	1.25% Notes due 2018	2.625% Notes due 2041	2.625% Notes due 2041	2.625% Notes due 2041
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Convertible notes interest rate percentage	0.50%	0.50%	0.50%	1.25%	1.25%	1.25%	2.63%	2.63%	2.63%
Debt instruments maturity date	'2016	'	'	'2018	'	'	'2041	'	'

Recovered_Sheet2

Long-Term Debt and Other Borrowings - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Share data in Millions, except Per Share data, unless otherwise specified

31-May-11

Mar. 30, 2014

Dec. 29, 2013

Jun. 30, 2013

Mar. 12, 2014

Mar. 30, 2014

Dec. 29, 2013

Jun. 30, 2013

Mar. 30, 2014

Jun. 24, 2012

Mar. 30, 2014

Jun. 30, 2013

31-May-11

Mar. 30, 2014

Jun. 30, 2013

Mar. 30, 2014

31-May-11

Mar. 30, 2014

Jun. 30, 2013

Mar. 30, 2014

Revolving credit facility

Minimum

Maximum

2.625% Notes due 2041

0.50% Notes due 2016

1.25% Notes due 2018

Prime Rate

Federal Funds Rate

Revolving credit facility

Convertible Note Hedge

London Interbank Offered Rate (LIBOR)

Debt Instrument [Line Items]

Notes due

$700,000,000

$699,900,000

$450,000,000

Convertible notes interest rate percentage

2.63%

0.50%

1.25%

Initial conversion rate of common stock shares

28.4781

15.8687

Principal amount of convertible debt conversion increments

1,000

Convertible Senior Notes conversion price

$35.11

$63.02

Net proceeds from the sale of Convertible Senior Notes

835,500,000

Debt instruments maturity date

'2041

'2016

'2018

Maximum amount of contingent interest rate

2.10%

Initial carrying value of liability component of convertible notes

509,500,000

373,800,000

345,100,000

Discount rate used to determine liability fair value

4.28%

4.29%

5.27%

Carrying value of equity components

328,100,000

76,200,000

104,900,000

Effective interest rates on the liability component

4.28%

4.29%

5.27%

Unamortized discount balance

184,200,000

186,900,000

34,300,000

45,700,000

66,300,000

76,900,000

Remaining life of bond discount, years

'27 years 1 month 6 days

'2 years 1 month 6 days

'4 years 1 month 6 days

If-converted value in excess of aggregate principal amount

386,300,000

Warrant conversion price

71.34

76.1

Shares issued under warrants

7.1

Shares of common stock agreed to sell

7.1

Period of time that common stock sale price for preceding quarter exceeds conversion price

'20 days

Number of consecutive trading days period required

'30 days

Stock price percentage of conversion price

130.00%

Fair value of notes

1,196,900,000

518,600,000

558,400,000

Revolving unsecured credit facility

300,000,000

Credit Facility Maturity Period

12-Mar-19

Additional increase in the facility

200,000,000

Revolving unsecured credit facility maximum borrowing capacity

500,000,000

Debt instrument basis spread on variable rate

0.50%

0.90%

0.00%

1.50%

0.50%

Total consolidated indebtedness to capitalization ratio

50.00%

Consolidated debt to liquidity

1,000,000,000

Credit facility outstanding amount

Schedule_of_Recognized_Interes

Schedule of Recognized Interest Cost Relating to Both Contractual Interest Coupon and Amortization of Discount on Liability Component of Notes (Detail) (USD $)	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Debt Instrument [Line Items]	'	'	'	'
Amortization of interest discount	'	'	$24,652,000	$23,530,000
2016, 2018 and 2041 Senior Notes	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Contractual interest coupon	6,600,000	6,600,000	19,700,000	19,700,000
Amortization of interest discount	8,300,000	7,900,000	24,700,000	23,500,000
Amortization of issuance costs	600,000	600,000	1,800,000	1,800,000
Total interest cost recognized	$15,500,000	$15,100,000	$46,200,000	$45,000,000

Commitments_Additional_Informa

Commitments - Additional Information (Detail) (USD $)	9 Months Ended					9 Months Ended		12 Months Ended
	Mar. 30, 2014	Jun. 30, 2013		Mar. 30, 2014	Mar. 30, 2014	Mar. 30, 2014	Mar. 30, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Mar. 30, 2014
				Operating Lease Cash Collateral	Operating Lease Marketable Securities Collateral	Amended	Operating Leases	Operating Leases	Operating Leases	Operating Leases	Standby Letters of Credit
								Leases	Amended And Restated	Amended
									Leases	Leases
Commitments [Line Items]	'	'		'	'	'	'	'	'	'	'
Number of operating leases extinguished	'	'		'	'	'	'	2	'	'	'
Number of operating leases	'	'		'	'	'	'	'	4	6	'
Approximate Operating Lease term, years	'	'		'	'	'7 years	'	'	'	'	'
Operating Leases expiration date	'	'		'	'	31-Dec-20	'	'	'	'	'
Operating Lease purchase option notification period, days	'30 days	'		'	'	'	'	'	'	'	'
Restricted collateral for leasing arrangements	$143,914,000	$166,536,000	[1]	$132,500,000	$6,100,000	'	'	'	'	'	'
Operating Lease residual value of guarantee, maximum	'	'		'	'	'	191,200,000	'	'	'	'
Maximum percentage of aggregate investment value guaranteed	'	'		'	'	'	100.00%	'	'	'	'
Guarantee Obligation Maximum Exposure	'	'		'	'	'	$220,000,000	'	'	'	$20,900,000

[1]	Derived from audited financial statements

Schedule_of_Changes_in_Product

Schedule of Changes in Product Warranty Reserves (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Product Warranty Liability [Line Items]	'	'	'	'
Balance at beginning of period	$67,413	$62,922	$58,078	$70,161
Warranties issued during the period	25,106	18,829	67,405	53,377
Settlements made during the period	-19,686	-27,101	-52,958	-72,960
Changes in liability for pre-existing warranties	-258	90	50	4,162
Balance at end of period	$72,575	$54,740	$72,575	$54,740

Restructuring_and_Impairments_

Restructuring and Impairments - Additional Information (Detail) (USD $)	Mar. 30, 2014
In Millions, unless otherwise specified	Mar. 30, 2014
Restructuring Cost and Reserve [Line Items]	'
Restructuring liability assumed in the Novellus acquisition	$10.30

Stock_Repurchase_Program_Addit

Stock Repurchase Program - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Mar. 30, 2014

Mar. 31, 2013

Mar. 30, 2014

Apr. 30, 2013

Apr. 30, 2014

Oct. 28, 2013

Mar. 30, 2014

Maximum

Repurchase Of Equity

Subsequent Event

Share Repurchase Program Final Settlement

Share Repurchase Arrangements

Maximum

Repurchase Of Equity

Initial delivery

Subsequent delivery

Maximum

Stock Repurchase Program [Line Items]

Authorized repurchase of Company common stock

$250,000,000

$850,000,000

Net shares of settlements to cover tax withholding obligations

468,585

Amount paid for shares under net share settlements

23,900,000

Treasury stock purchases

204,610,000

953,386,000

75,000,000

Total Number of Shares Repurchased

930,000

762,000

1,935,000

1,700,000

1,200,000

300,000

Treasury stock purchases, weighted average share price

$53.13

[1]

$52.20

[1]

$48.06

[1]

$50.40

Treasury stock, at cost

$75,000,000

[1]

Average price paid per share excludes accelerated share repurchases for which cost was incurred during the September 2013 quarter, but that did not settle until the December 2013 quarter. See Collared Accelerated Share Repurchases section below for details regarding average price associated with these transactions.

Schedule_of_Repurchases_under_

Schedule of Repurchases under 2013 Repurchase Program (Detail) (USD $)	3 Months Ended						12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 30, 2014		Dec. 29, 2013		Sep. 29, 2013		Jun. 30, 2013
Stock Repurchase Program [Line Items]	'		'		'		'
Total Number of Shares Repurchased	930		762		1,935		'
Total Cost of Repurchase	$49,414		$39,800		$96,462		'
Average Price Paid Per Share	$53.13	[1]	$52.20	[1]	$48.06	[1]	'
Amount Available Under Repurchase Program	$64,324		$113,738		$153,538		$250,000

[1]	Average price paid per share excludes accelerated share repurchases for which cost was incurred during the September 2013 quarter, but that did not settle until the December 2013 quarter. See Collared Accelerated Share Repurchases section below for details regarding average price associated with these transactions.

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	1 Months Ended
In Millions, except Per Share data, unless otherwise specified	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2014
	Repurchase Of Equity	Subsequent Event	Subsequent Event
	Maximum	Repurchase Of Equity	Dividend Declared [Member]
		Maximum
Subsequent Event [Line Items]	'	'	'
Declared dividend	'	'	$0.18
Authorized repurchase of Company common stock	$250	$850	'